























diseases;	 malaria	 and	 toxoplasmosis.	 Malaria	 affects	 two	 billion	 people	
worldwide	in	some	of	the	poorest	regions	of	the	world.	Over	a	million	people	
a	 year	 die	 from	 malaria,	 the	 majority	 of	 which	 are	 pregnant	 women	 or	
children	under	the	age	of	5.	Plasmodium	falciparum	 is	by	far	the	most	lethal	
cause	 of	 malaria	 and	 is	 endemic	 to	 many	 regions	 of	 sub-Saharan	 Africa.	
Toxoplasma	gondii	 is	 the	most	 common	 parasitic	 infection	 of	 human	 brain	
and	eyes	and	is	suspected	to	affect	one	third	of	the	world’s	population.	Rising	
drug	 resistance	and	 the	 inadequacies	of	 current	 treatments	have	 spurred	a	
global	effort	for	the	development	of	new	therapies	targeting	these	parasites	
	
	 Cytochrome	bc1	 (cyt.	bc1)	 is	a	proven	drug	 target	 for	both	 treatment	
and	prophylaxis	of	P.	falciparum	and	T.	gondii.	Atovaquone,	a	potent	broad-
spectrum	 anti-parasitic	 drug,	 targets	 the	 Qo	 site,	 one	 of	 two	 active	 sites	
within	cytochrome,	b	collapsing	 the	mitochondrial	membrane	potential	and	
killing	 the	parasites.	Single	mutations	within	 the	Qo	site	 render	atovaquone	
ineffective	 and	 incidences	 of	 resistance	 are	 rising.	 Previous	 work	 has	
focussed	 on	 overcoming	 resistance	 through	 the	 design/redesign	 of	
compounds	targeting	the	well	understood	Qo	site.	Here	we	show	the	binding	
modes	 of	 GSK’s	 next-generation	 antimalarial	 4(1H)-pyridones	 and	 a	 novel	
4(1H)-quinolone	 to	 the	 Qi	 site	 of	 cyt.	 bc1.	 These	 structures	 reveal	 the	
mechanism	 by	 which	 the	 compounds	 are	 able	 to	 overcome	 resistance	 and	
point	 in	 a	 new	 direction	 for	 antimalarial	 drug	 development.	 This	 work	
reaffirms	the	importance	of	structural	observation	in	drug	development.	
	
	 Merozoite	 surface	 protein	 1–19	 (MSP119)	 is	 an	 important	 target	 in	
vaccine	 development	 against	 malaria.	 Recent	 work	 has	 shown	 that	
cupredoxins	bind	MSP119	of	P.	falciparum	and	result	in	death	for	the	parasite.	
Rusticyanin,	 the	 most	 potent	 of	 these,	 has	 been	 extensively	 studied	 and	
various	mutants	 have	 been	 produced	 a	 range	 of	 redox	 potentials	 and	 acid	
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pathogens	 responsible	 for	 the	 diseases	 malaria	 and	 toxoplasmosis	
respectively.	Both	of	these	illnesses	can	be	highly	incapacitating	and	may	be	





Malaria	 is	 a	 catastrophic	 illness	 endemic	 to	many	of	 the	poorest	 regions	of	
the	world.	 It	 is	a	mosquito-borne	disease	caused	by	protozoan	apicomplexa	
parasites	of	the	genus	Plasmodium.	The	evidence	for	cases	of	malaria	and	its	
characteristic	 fever	 can	 be	 traced	 back	 to	 pre-history	 and	 the	 disease	was	
once	found	on	every	continent	of	the	world,	excluding	Antarctica	(Neghina	et	
al.	 2010).	 The	 first	 direct	 evidence	 of	 the	Plasmodium	 spp.	parasite	 and	 its	
role	 in	malaria	 came	 in	 1880.	 Charles	 Louis	 Alphonse	 Laveran,	who	would	
later	win	the	Nobel	Prize	 in	1907	 for	his	work,	described	the	parasite	 from	
microscopy	of	red	blood	cells	from	a	patient	who	had	recently	died	(Laveran	










strain	 on	 national	 resources	 and	 halts	 development	within	 these	 countries	
which	further	exacerbates	the	problem	(Breman	2001;	Gallup	&	Sachs	2001).	
	
	 Malaria	 symptoms	 are	 typically	 flu-like	 and	 include	 fever,	 chills,	
sweating	and	headaches	(Bartoloni	&	Zammarchi	2012).	Symptoms	present	
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after	 an	 incubation	 period	 within	 the	 host	 that	 varies	 in	 time;	 typically	
between	 8	 and	 30	 days.	 The	malarial	 fever	 is	 periodic	 and	 recurrent.	 The	
time	between	fevers	is	dependent	on	the	species	of	Plasmodium	causing	the	
infection	 varying	 from	 almost	 daily	 fevers	 in	 P.	 falciparum	 to	 months	 in	
between	fevers	for	P.	malariae	 .	Severe	malaria	is	almost	exclusively	caused	
by	 P.	 falciparum	 (also	 known	 as	 falciparum	 malaria)	 due	 to	 the	 unique	
presentation	of	 sequestration	 (Dondorp	et	 al.	 2004).	This	occurs	as	mature	
forms	 of	 the	 parasite	 within	 red	 blood	 cells	 (RBCs)	 alter	 the	 surface	
properties	of	 the	cell	 causing	 them	to	adhere	 to	 the	endothelium	and	block	






	 There	 are	 many	 species	 of	 the	 protozoan	 Plasmodium	 that	 infect	 a	
variety	 of	 animal	 species	 including	 many	 primates,	 rodents	 and	 birds.	
Humans	 are	 affected	 by	 several	 Plasmodium	 species	 but	 two	 species	 in	
particular	account	for	the	majority	of	infections	and	deaths:	P.	falciparum	and	
P.	vivax	(Carter	&	Mendis	2002).	P.	falciparum	is	by	far	the	most	lethal	of	the	






temperatures	 than	 P.	 falciparum,	 which	 extends	 its	 range	 of	 infection	
(Gething	 et	 al.	 2011).	 P.	 vivax	 also	 forms	 hypnozoites	 that	 can	 remain	











Yellow	 indicates	between	0	–	50	deaths,	orange	 for	51	–	500	deaths,	 red	shows	501	–	





Like	all	Plasmodium	spp.,	 the	P.	falciparum	parasite	has	a	 complex	 life	 cycle	
that	 requires	 both	 a	 host	 and	 mosquito	 vector	 (Figure	 1.2).	 The	 female	
Anopheles	 gambiae	 mosquito	 is	 particularly	 prevalent	 in	 the	 spread	 of	 P.	
falciparum;	 the	 male	 does	 not	 feed	 on	 blood	 (Fontenille	 &	 Simard	 2004).	
Human	 infection	 begins	 when	 an	 infected	 mosquito	 bites	 the	 host.	 This	
spreads	 sporozoites	 to	 the	host	 from	 the	mosquitos’	 salivary	 glands,	which	
quickly	accesses	 the	bloodstream	and	 spread	 to	 the	 liver	where	 they	 infect	
the	 hepatocytes	 in	 a	matter	 of	minutes.	 Upon	 entering	 the	 hepatocytes	 the	
sporozoites	differentiate	and	become	trophozoites	within	a	parasitophorous	
	





vacuole	 where	 they	 multiply	 and	 eventually	 become	 merozoites.	 The	
infection	remains	asymptomatic	for	around	five	and	a	half	days	yielding	tens	
of	thousands	of	merozoites	which	then	emerge	and	proceed	to	invade	RBCs	
before	 returning	 to	 a	 trophozoite	 form	where	 it	 grows	 into	 a	 schizont.	The	
schizonts	 replicate	 and	 produce	 between	 8	 –	 20	 new	merozoites	 every	 48	
hours.	The	merozoites	rupture	the	RBCs,	exit	and	quickly	attach	to	and	infect	




through	 gametocytogenesis.	 These	 cells	 are	 non-pathogenic	 and	 remain	 in	
the	blood	cells	until	 ingestion	by	a	mosquito	for	further	development.	Upon	
ingestion	the	cells	fuse	to	form	a	genetically	unique	zygote	that	then	develops	
into	 an	 ookinete.	 It	 is	 possible	 for	 gametocytes	 from	 different	 parental	
parasites	 can	 fuse	 depending	 on	 the	 frequency	 of	 the	 blood	 meal.	 The	
ookinete	exits	the	midgut	and	further	develops	to	produce	sporozoites	in	the	





global	health	organisations	and	 local	governments	 for	decades	 (Greenwood	
et	al.	2008;	Mendis	et	al.	2009;	Nájera	et	al.	2011).	Overall,	this	has	resulted	
in	 a	 largely	 successful	 reduction	 of	 the	 geographic	 spread	 of	 malaria.	 The	
continents	of	North	America	and	Europe	were	both	identified	as	malaria	free	
in	the	second	half	of	19th	century.	In	1955,	following	the	development	of	the	







Health	Organization	 1969).	 This	 failure	was	 a	 result	 of	 rising	 resistance	 to	





	 Efforts	 against	malaria	 increased	 again	 in	 early	 1990s,	 as	 the	 global	
burden	of	malaria	reached	a	peak	(Snow	et	al.	2001).	The	Roll	Back	Malaria	
Partnership	began	work	towards	malaria	control	and	elimination	 in	several	
countries	 and	 has	 resulted	 in	 the	 Global	 Malaria	 Action	 plan.	 With	 the	
development	 of	 new	 tools	 and	 resources	 such	 as	 the	Malaria	 Atlas	 Project	
(MAP)	 (Hay	 &	 Snow	 2006),	 successes	 in	 burden	 reduction	 of	 several	
countries	 (Nyarango	 et	 al.	 2006),	 and	 renewed	 public	 interest,	 malaria	
eradication	 appears	 to	 be	 possible	 but	 only	 if	 the	 lessons	 of	 previous	
attempts	have	been	learnt	(Mendis	et	al.	2009;	Lines	et	al.	2007).	There	have	






where	 malaria	 had	 previously	 no	 longer	 been	 endemic	 (Siraj	 et	 al.	 2014;	
Caminade	 et	 al.	 2014).	 Global	 programs	 for	 control	 and	 elimination	 also	







Combatting	malaria	 is	 a	 complex	 problem	 that	will	 require	 a	multi-
vector	solution.	 In	 the	 long	term,	 infrastructure	 in	endemic	countries	needs	
	 15	
to	 be	 improved	 to	 allow	 better	 monitoring,	 increased	 hygiene	 and	 faster	
response	 times	 (Breman	 2001;	 Carter	 &	 Mendis	 2002;	 Rafael	 et	 al.	 2006;	
Chareonviriyaphap	et	al.	2000).	In	the	short	term,	both	control	of	the	vector,	





limit	 their	 numbers	 and	 therefore	 the	 spread	 of	 malaria.	 Mosquitos	 have	
been	 targeted	 and	 displaced	 from	 local	 areas	 through	 the	 removal	 of	 still	
water	 that	 acts	 as	 breeding	 grounds	 or	 the	 introduction	 of	 fish	 to	 eat	 the	
larvae	before	they	are	able	to	grow	into	adult	mosquitos	(Keiser	et	al.	2005;	
Chandra	 et	 al.	 2008).	 Genetically	 modified	 mosquitos	 have	 also	 been	
developed	 and	 long	 debated	 as	 a	 way	 of	 transmission	 control	 through	
various	 genetic	manipulations	 (Benedict	 &	 Robinson	 2003;	Marinotti	 et	 al.	






Paul	Hermann	Müller	was	awarded	 the	Nobel	Prize	 in	1948	 (Muller	1946).	
DDT	 fell	 out	 of	 favour	 as	 an	 insecticide	 due	 to	 both	 the	 emergence	 of	
resistance	and	toxicity	issues	(Georgopoulos	1954;	Roberts	et	al.	2000).	It	is	
however,	 still	 used	 for	 Indoor	Residual	 Spraying	 (IRS),	 a	 process	 by	which	
the	 interior	 walls	 of	 a	 building	 are	 coated	 with	 insecticide	 (Roberts	 2007;	
Roberts	 et	 al.	 2000).	 After	 a	 blood	 meal,	 the	 mosquito	 lands	 on	 the	 wall,	
making	contact	with	the	insecticide	and	dies.	This	has	been	shown	to	greatly	
reduce	vector	 transmission	 (Hemingway	2014).	Nets	 can	also	be	used	over	
beds	 to	 prevent	 the	 infection	 of	 sleeping	 individuals	 and	 are	 particularly	
useful	when	 combined	with	 insecticides	 as	 Insecticide	 Treated	Nets	 (ITNs)	
(Phillips-Howard	et	al.	2003;	Alonso	et	al.	1991).	Black	market	bed	nets	and	
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unregulated	 agricultural	 use	of	 insecticides	have	 led	 to	 the	development	of	
resistance	to	even	the	latest	insecticides	(Edi	et	al.	2012;	Elissa	et	al.	1993).	
DDT	 has	 recently	 been	 reintroduced	 for	 IRS	 and	 research	 is	 on	 going	 into	
newer,	 more	 long-term	 insecticides	 for	 use	 with	 ITNs.	 Entomopathogenic	
fungi	 have	 recently	 been	 suggested	 as	 a	 biopesticide	 for	 use	 with	 ITNs	 to	








vaccine	 development	 targeting	 different	 stages	 of	 the	 life	 cycle	 with	 little	
success.	 Recently,	 the	 vaccine	 RTS,S/AS01	 (trade	 name	 Mosquirix™)	 has	
concluded	 phase	 III	 clinical	 trials	 and	 has	 been	 approved	 by	 the	 European	
Medicines	 Agency	 (European	 Medicines	 Agency	 2015).	 It	 has	 substantially	
reduced	 cases	 of	malaria	 in	 children	 (RTS	 2015)	 although	 vaccine	 efficacy	







parasite	 undergoes	 dramatic	 proteomic	 shifts	meaning	 several	 targets	 that	
are	present	 in	one	stage	will	not	be	present	 in	others	 (Florens	et	al.	2002).	
Drug	resistance	has	been	seen	in	Plasmodium	against	all	current	treatments	
(Pradines	 et	 al.	 2006).	 Resistance	 can	 emerge	 rapidly	 to	 monotherapy	
treatments	 and	 so	 combination	 therapies	 have	 become	 ubiquitous.	 This	
increases	the	price	of	treatment	but	helps	combat	resistance	and	was	issued	







Quinolines	 are	 a	 class	 of	 antimalarial	 medication	 thought	 to	 act	
through	 the	 inhibition	 of	 hemozoin	 biocrystallisation	 resulting	 in	 an	
increased	 level	 of	 free	 heme	 within	 the	 RBCs	 (Warhurst	 &	 Hockley	 1967;	
Slater	 &	 Cerami	 1992).	 The	 increase	 in	 toxic	 free	 heme	 is	 lethal	 to	 the	
reproducing	merozoites.	Chloroquine	was	developed	in	the	early	20th	century	
as	 a	 synthetic	 substitute	 for	 quinine	 and	 became	 the	 key	 treatment	 and	
prevention	 of	malaria.	Due	 to	 its	 low	 cost	 and	high	 efficacy,	 it	was	 used	 in	
early	attempts	at	malaria	eradication	as	a	monotherapy.	Since	 then,	several	
other	quinolones	have	been	developed	which	are	believed	to	act	in	a	similar	
manner	 (Sullivan	 et	 al.	 1998).	 These	 include	 amodiaquine,	mefloquine	 and	
primaquine.	 Resistance	 to	 chloroquine	 took	 some	 time	 to	 develop	 but	 first	
emerged	 in	 South	 East	 Asia	 and	 is	 now	 widespread	 in	 P.	 falciparum	
(Harinasuta	 et	 al.	 1965;	 Wongsrichanalai	 et	 al.	 2002).	 It	 is	 still	 used	 as	
treatment	of	some	cases	of	P.	vivax	in	certain	regions	of	the	world,	in	part	due	
to	its	low	cost	(Wellems	&	Plowe	2001;	Laufer	et	al.	2006).	Resistance	is	also	
present	 against	 all	 other	 quinoline	 derivatives.	 The	 rise	 of	 P.	 falciparum	
resistance	 in	 Africa	 resulted	 in	 a	 much	 higher	 mortality	 than	 elsewhere	
(Trape	 et	 al.	 1998).	 Several	 of	 the	 quinoline	 compounds	 produce	 adverse	




Antifolates	 including	 proquanil	 (Carrington	 et	 al.	 1951)	 and	
cyloguanil,	sulfadoxine	(Laing	1964)	and	pyrimethamine	(Russel	&	Hitchings	



















































































































































dihydropteroate	 synthase	 (DHPS)	 downstream	 pyrimidine	 and	 purine	






Atovaquone	 is	 the	 only	 current	 hydroxynapthoquinone	 licensed	 for	
malaria	 treatment	 and	 prophylaxis	 (Looasreesuwon	 et	 al.	 1999).	 The	 drug	
was	 a	 result	 of	 rational	 drug	 design	 by	 GSK	 (Gutteridge	 1989)	 and	 is	
marketed	as	Malarone™	when	sold	in	combination	with	proguanil.	It	is	one	of	
the	 most	 popular	 medications	 for	 prophylaxis	 amongst	 travellers	 (Nixon,	
Moss,	 et	 al.	 2013).	 Atovaquone	 is	 a	 ubiquinone	 analogue	 that	 acts	 on	 the	
cytochrome	bc1	complex	(cyt.	bc1)	of	the	parasite	mitochondria	by	inhibiting	
the	 Qo	 site	 (Fry	 &	 Pudney	 1992;	 Siregar	 et	 al.	 2015;	 Birth	 et	 al.	 2014).	
Resistance	emerges	rapidly	when	used	as	a	monotherapy	and	a	single	point	
mutation	 within	 the	 Qo	 site	 of	 the	 cytochrome	 b	 (cyt.	 b)	 gene	 prevents	
atovaquone	 action	 (Korsinczky	 et	 al.	 2000;	 Fisher	&	Meunier	 2008).	 As	 its	
mechanism	of	action	 is	 fairly	well	understood,	cyt.	bc1	 is	a	strong,	validated	
target	 for	 next-generation	 antimalarials	 (Barton	 et	 al.	 2010).	 Research	 has	
continued	 into	 the	 hydroxynapthoquinones	 and	 has	 resulted	 in	 several	




Artemisinin	 had	 been	 used	 to	 treat	 malaria	 as	 a	 herbal	 tea	 for	
millennia	 and	 now	 forms	 the	 basis	 of	 artemisinin-based	 combination	
therapies	(ACTs).	It	was	first	extracted	and	identified	from	the	tree	Artemisia	
annua	in	1972	(Qinghaosu	Antimalarial	Co-ordinating	Research	Group	1979)	
by	 Chinese	 scientists	 and	 has	 been	 proven	 to	 be	 a	 rapid	 and	 potent	
antimalarial	 (Klayman	 1985).	 Its	 synthetic	 derivatives	 artesunate,	
artemether	 and	 dihydroartemisinin	 have	 also	 proven	 highly	 effective.	 The	
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peroxide	bridge	 located	within	the	compound	 is	 thought	 to	be	the	essential	
moiety.	The	mode	of	action	is	largely	unknown,	although	evidence	points	to	
the	 parasite	 mitochondria	 as	 its	 site	 of	 action,	 where	 the	 generation	 of	
reactive	oxygen	species	(ROS)	and	the	collapse	of	mitochondrial	polarisation	
appear	to	be	important	(Wang	et	al.	2010;	Antoine	et	al.	2013).	Artemisinin	is	
a	 rapid	 action	 drug	 and	 usually	 used	 in	 combination	 with	 a	 longer	 acting	
compound	 to	 prevent	 recurrence.	 Resistance	 has	 been	 seen	 in	 South	 East	
Asia	 and	 is	 spreading	 quickly	 through	 an,	 as	 of	 yet,	 unknown	 mechanism	
(Dondorp	 et	 al.	 2009;	 Phyo	 et	 al.	 2012).	 ACTs	 currently	 form	 the	 gold	
standard	 of	 treatment	 in	 the	 majority	 of	 countries	 against	 malaria	 and	 if	
resistance	 were	 to	 arise	 in	 P.	 falciparum	 populations	 in	 Africa,	 the	 results	
could	 be	 highly	 damaging	 (Maude	 et	 al.	 2010).	 Multiple	 methods	 to	 avoid	
resistance	 have	 been	 suggested	 including	 the	 use	 of	 triple	 combinations	
including	 artemisinin,	 which	 would	 help	 combat	 resistance	 but	 make	 the	







Those	 novel	 compounds	 are	 of	 particular	 interest	 as	 resistance	 to	 these	 is	
less	 likely	 under	 current	 selection	 pressure.	 A	 large	 number	 of	 these	 are	





Toxoplasmosis	 is	 caused	 by	 the	 protozoan	 T.	 gondii	 and	 affects	




infections	 remain	 asymptomatic	 and	 go	 unnoticed	 as	 latent	 toxoplasmosis	
(Robert-Gangneux	 &	 Dardé	 2012).	 In	 infections	 of	 pregnant	 women	 it	 can	
cause	 the	 birth	 of	 infants	 with	 congenital	 disease	 or	 abortion	 (Montoya	 &	
Remington	 2008).	 The	 congenital	 disease	 can	 cause	 both	 blindness	 and	
mental	 retardation	 in	 infants.	 In	 immunocompromised	 patients,	 such	 as	
those	 suffering	 from	 acquired	 immune	 deficiency	 syndrome	 (AIDS),	
toxoplasmic	 encephalitis	 can	 occur	 causing	 severe	 brain	 damage	 (Luft	 &	
Remington	 1992;	 Snider	 et	 al.	 1983).	 Latent	 toxoplasmosis	 alters	 the	
behaviour	 of	 infected	 animals	 resulting	 in	 an	 increased	 transmission	 rate.	
Rodents	 that	 are	 infected	 show	 slower	 reaction	 times,	 reduced	 cognitive	
learning	and	memory	and	changes	in	the	olfactory	system	resulting	in	“fatal	
attraction”	 to	 cat’s	 urine	 (Berdoy	 et	 al.	 2000).	 Several	 studies	 have	 been	
carried	 out	 in	 an	 attempt	 to	 determine	 any	 mental	 changes	 that	 occur	 in	
infected	 humans	 (Flegr	 2013).	 These	 have	 indicated	 a	 link	 between	 the	




The	 T.	 gondii	 life	 cycle	 consists	 of	 two	 parts	 and	 has	 been	 extensively	
reviewed	elsewhere	(Dubey	1998;	Dubey	2009;	Black	&	Boothroyd	2000).	An	
asexual	cycle	within	a	warm	blooded	mammalian	host	and	a	sexual	cycle	that	
obligately	 occurs	within	 a	 feline	 (Figure	1.3).	Once	 infected,	 usually	 from	a	
rodent	 meal,	 the	 parasites	 differentiate	 into	 infective	 merozoites	 before	
entering	 the	 sexual	 stage	 and	 forming	 zygote-containing	 cysts.	 These	 cysts	
are	called	oocysts	and	develope	within	the	epithelium	of	the	feline	intestinal	
wall.	The	epithelium	ruptures	 causing	 the	exit	 of	 oocysts	within	 the	 faeces.	






	 Upon	 infection	 of	 an	 intermediate	 host,	 either	 by	 ingestion	 of	
contaminated	food	or	contact	with	feline	oocysts,	cysts	rupture.	This	occurs	
as	 a	 result	 of	 the	 digestive	 properties	 of	 the	 stomach	 and	 releases	
sporozoites.	The	 sporozoites	 then	 embed	 themselves	within	 the	 epithelium	
of	 the	small	 intestine	and	differentiate	 into	 tachiozoites,	 the	acute,	 infective	





any	 organ	 but	 are	 primarily	 found	 in	 striated	 muscle,	 eye	 or	 brain	 tissue.	
	
Figure	 1.3	 |	 The	 life	 cycle	 of	Toxoplasma	gondii.	 The	 sexual	 stage	must	 taken	 place	 in	 a	
feline	 host	 whilst	 the	 asexual	 stage	 can	 take	 place	 in	 almost	 any	 warm	 blooded	 animal.	








cat	 faeces	 or	 from	 the	 consumption	 of	 contaminated	meat.	 Non-congenital	
patients	 typically	 show	minimal	 symptoms	 and	 rarely	 suffer.	 AIDs	 patients	




The	 current	 standard	 treatment	 of	 toxoplasmosis	 is	 a	 synergistic	
combination	 of	 pyrimethamine	 and	 sulfadiazine	 (Montoya	 &	 Liesenfeld	
2004).	 Pyrimethamine	 inhibits	 the	 same	 target	 as	 in	 P.	 falciparum,	
dihydrofolate	 reductase	 (DHFR),	 whilst,	 sulfadiazine	 inhibits	
dihydropteroate	 synthase	 (DHPS).	By	 inhibiting	multiple	 steps	of	 the	 folate	
biosynthesis	 pathway,	 this	 combination	 reduces	 the	 availability	 of	 folate	
compounds	that	are	essential	for	parasite	survival.	The	treatment	can	also	be	
supplemented	 with	 folinic	 acid	 to	 increase	 efficacy	 and	 reduce	 adverse	
effects	(Van	Delden	&	Hirschel	1996).	Due	to	toxicity,	these	compounds	often	
cannot	 be	 used	 for	 an	 extended	 period	 of	 time	 in	 immunocompromised	
patients	(Leport	et	al.	1988).	Resistance	can	also	occur	to	these	compounds	
and	variation	in	parasite	susceptibility	 is	a	treatment	 issue	(Meneceur	et	al.	




Atovaquone	 is	 active	 against	 tachyzoites	 at	 low	 concentrations	 and	
also	treats	bradyzoites	within	cysts	(Araujo	et	al.	1992;	Ferguson	et	al.	1994).	
Atovaquone	is	also	beneficial	as	it	can	be	used	in	AIDS	patients	due	to	lack	of	
adverse	 side	 effects	 (Kovacs	 &	 NIAID-Clinical	 Center	 Intramural	 AIDS	
Program	 1992).	 Atovaquone	 acts	 through	 a	 similar	 mechanism	 as	 in	 P.	
falciparum	and	has	been	shown	to	bind	the	Qo	site	of	cyt.	b	within	T.	gondii	
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cyt.	 bc1.	 Unlike	 in	 P.	 falciparum,	 de	 novo	 pyrimidine	 biosynthesis	 is	 not	
thought	to	be	the	primary	mechanism	of	action	and	respiration	has	been	seen	
to	 be	 reduced	 (Pfefferkorn	 et	 al.	 1993).	 Drug	 resistance	 has	 been	 detected	




Both	malaria	 and	 toxoplasmosis	 affect	 some	of	 the	world’s	 poorest	 regions	
and	 are	 the	 cause	 for	 large-scale	 suffering	 and	 death.	 Despite	 the	 huge	
amount	 of	 malaria	 awareness,	 it	 remains	 one	 of	 the	 largest	 killers	 in	 the	
world	 today	 particularly	 in	 the	 poorer	 regions	 of	 the	world	where	 funding	
does	not	reach	the	required	level	(Mills	et	al.	2008).	Malaria	deaths	reached	a	
peak	 in	2004	of	1,817,000	worldwide	and	1,613,000	within	Africa	but	have	
shown	a	promising	decline	over	 recent	 years	 (Murray	 et	 al.	 2012).	Though	
reduced,	 this	 is	 still	 more	 deaths	 worldwide	 than	 those	 caused	 by	 traffic	
accidents	(1.24	million	deaths	each	year)	(World	Health	Organization	2013).	
Global	warming	and	the	increasing	spread	of	drug	resistance	have	created	a	
dire	 need	 for	 the	 development	 of	 new	 compounds	 that	 are	 both	 easy	 and	
cheap	to	produce	whilst	remaining	effective	against	drug-resistant	malaria.	If	
malaria	 eradication	 is	 to	 prove	 a	 realistic	 target,	 an	 increased	 range	 of	
antimalarial	drugs	will	be	an	essential	tool	alongside	insecticides,	nets	and	a	
potential	future	vaccine	as	well	as	improvement	in	general	infrastructure	and	
living	 conditions.	 Malaria	 and	 toxoplasmosis	 share	 a	 common	 drug	 target,	
cyt.	bc1.	Inhibition	of	this	target	is	lethal	at	all	stages	of	development	for	both	
P.	 falciparum	 and	T.	gondii	(Araujo	 et	 al.	 1992;	 Fleck	 et	 al.	 1996).	 This	 has	
made	cyt.	bc1	a	promising	target	for	the	development	of	drugs	against	these	
protozoa.	 Drug	 development	 benefits	 from	 a	 clear,	 strong	 target	 and	
structural	information	to	guide	the	design	pipeline.	X-ray	crystallography	can	










The	 vast	 majority	 of	 drug	 targets	 are	 proteins.	 By	 studying	 the	 role	 of	 a	
protein	 in	 a	 disease,	 it	 can	 be	 hypothesised	 whether	 a	 potential	 drug,	 or	
changes	 to	 a	 potential	 drug,	 would	 have	 a	 beneficial	 therapeutic	 effect.	
Membrane	proteins	are	estimated	to	make	up	30	%	of	the	human	proteome	
(Krogh	 et	 al.	 2001)	 and	potentially	 60	%	of	 all	 drug	 targets	 (Yildirim	et	 al.	
2007;	 Bakheet	 &	 Doig	 2009).	 The	 membrane	 bound	 G-protein	 coupled	
receptors	(GPCRs)	as	a	class	of	drug	target	make	up	approximately	50	%	of	
drug	 targets	alone	 (Overington	et	al.	2006).	Drug	discovery	has	historically	
relied	 on	 chance,	 such	 as	 the	 discovery	 of	 penicillin,	 or	 the	 isolation	 of	













years.	NCEs	 can	be	 pulled	 at	 any	 time	during	 trials	 due	 to	 lack	 of	 effect	 or	
perceived	 toxicity	 and	 surveillance	 continues	 throughout	 the	drugs	 lifetime	
to	assure	the	absence	of	long-term	toxic	effects.	The	majority	of	NCEs	fail	to	






Modern	 drug	 discovery	 has	 moved	 away	 from	 the	 serendipitous	
methods	 that	 preceded	 it	 and	 has	 moved	 towards	 rational	 drug	 design	
(Drews	2000).	Drug	development	now	begins	with	the	validation	of	a	known	
molecular	 target	 against	 which	 a	 lead	 compound	 is	 identified.	 This	
identification	usually	requires	high	throughput	screening	(HTS)	in	vitro	or	in	
silico	 using	 a	 diverse	 chemical	 library.	 Compounds	 that	 appear	 to	 prove	
beneficial,	 “hits”,	 can	 then	 be	 optimised	 through	 several	 iterations	 of	
modification,	 testing	 and	 analysis	 into	 a	 lead	 compound	 (Figure	 2.1).	 The	
compound	is	modified	through	these	cycles	to	improve	the	efficacy	of	the	hit	
whilst	 maintaining	 several	 drug-like	 properties	 such	 as	 “Lipinski’s	 rule	 of	
five”	 (Lipinski	 et	 al.	 2001).	 Lipinski’s	 rule	 of	 five	 refer	 to	 properties	 that	 a	
drug	should	have	if	it	is	to	be	orally	administered.	These	include	a	molecular	






Figure	 2.1	 |	 The	 stages	 of	 drug	 development.	 After	 target	 identification	 and	 hit	
discovery,	drug	development	goes	through	several	rounds	of	analysis	and	modification	
to	improve	both	the	efficacy	and	drug-like	properties	of	the	compound.	Structure	based	




An	 extension	 of	 the	 rule	 of	 five,	 which	 defines	 properties	 of	 an	
effective	drug,	is	Astex’s	rule	of	three	(Congreve	et	al.	2003).	This	attempts	to	
define	good	lead	compounds	for	 initial	 library	screening,	which	can	then	be	
developed	 into	 a	 drug-like	 compound.	 These	 guidelines	 suggest	 that	 the	
fragment	should	have	a	molecular	mass	of	no	more	than	300	Da,	possess	no	
more	 than	 three	 hydrogen	 bond	 acceptors,	 no	 more	 than	 three	 hydrogen	





	 Compounds	 can	 be	 tailored	 through	 this	 development	 to	 assure	
beneficial	 absorption,	 distribution,	 metabolism,	 excretion	 and	 low	 toxicity	
(ADMET)	properties	 in	pre-clinical	stages.	ADMET	provides	a	 framework	to	
determine	 properties	 of	 a	 compound	 within	 a	 that	 are	 compatible	 with	 a	
drug-like	 compound.	 In	 silico	 work	 is	 now	 frequently	 carried	 out	 on	 lead	
compounds	 to	 determine	 the	 ADMET	 properties	 during	 development	 to	





Knowledge	 of	 a	 protein’s	 structure	 allows	more	 input	 into	 rational	 design	




Nuclear	Magnetic	Resonance	 (NMR)	or	X-ray	 crystallography.	 If	 a	 structure	
cannot	be	 solved,	 it	 is	 possible	 to	 create	 a	homology	model	using	 some	3D	
homology	modelling	servers	that	rely	on	the	structures	of	previously	solved	
protein	 structures	 with	 significant	 sequence	 identity	 (Hillisch	 et	 al.	 2004).	
SBDD	has	had	 a	huge	 impact	 on	drug	development	 since	 its	 beginning	 and	
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has	 played	 a	 role	 in	 bringing	 multiple	 pharmaceuticals	 to	 market	 (see	
Appendix	A),	including	a	number	of	blockbuster	drugs	(Table	2.1).		
	
Many	more	 compounds	 are	 currently	 being	 researched	 using	 SBDD	
pipelines,	 such	 at	 those	 as	 Contour®,	 Vitae	 (Ishchenko	 et	 al.	 2012)	 or	 the	
Pyramid™	platform,	Astex	(Williams	2011).	With	the	exponential	increase	in	
the	 number	 of	 available	 protein	 structures,	 particularly	membrane	 protein	
structures,	SBDD	is	continuing	to	grow	in	its	application.	This	is	particularly	
true	with	 regards	 to	 drug	 discovery	 against	 GPCRs	 as	 a	 result	 of	 the	work	
done	 by	 Heptares	 Therapeutics	 (www.heptares.com)	 to	 produce	 stable	
protein	 that	 can	 be	 crystallised.	 Specific	 research	 institutes	 have	 also	 been	




	 NMR	 can	 be	 used	 to	 solve	 the	 three	 dimensional	 (3D)	 structure	 of	














































dependant	 on	 isotope-labelled	 protein	 production	 for	 the	 study	 of	
macromolecules	but	proteins	over	30	kDa	generally	prove	difficult	for	NMR.	
NMR	is	not	highly	amenable	to	the	study	of	membrane	proteins,	which	also	
precludes	 it	 from	 studying	 the	 structures	 of	 60	%	 of	 drug	 targets.	 NMR	 is	
highly	 suitable	 for	 fragment	 based	 screening	 methods	 as	 differences	 in	
chemical	 shift	 can	 quickly	 be	 detected	 to	 reveal	 whether	 a	 compound	 has	
bound	 to	 the	 protein	 target	 and	 with	 what	 affinity	 (Shuker	 et	 al.	 1996;	
Hajduk	et	al.	1997).	NMR	also	requires	 less	of	the	molecule	to	 interact	with	










drug	 brought	 to	 market	 with	 the	 assistance	 of	 X-ray	 crystallographic	
structural	 information	 was	 Captopril,	 an	 angiotensin-converting	 enzyme	
(ACE)	inhibitor	primarily	used	in	the	treatment	of	hypertension	(Cushman	et	
al.	1977).	This	was	developed	using	a	homologous	bovine	protein	structure	
as	 little	was	known	of	 the	ACE	proteins	at	 the	 time.	Since	 then	many	other	
compounds	have	been	explored	and	approved	with	the	assistance	of	protein	
crystallography,	 including	 multiple	 HIV	 drugs	 in	 response	 to	 the	 AIDS	
epidemic	 (Debouck	 1992)	 and	 antiviral	 influenza	 drugs	 such	 as	 Zanamivir	
(von	Itzstein	et	al.	1993).	The	expansion	of	high	throughput-crystallography	






	 X-ray	crystallography	is	an	incredibly	 important	and	versatile	tool	 in	
the	 study	 of	 protein	 structure.	 Of	 the	 approximately	 112,000	 protein	
structures	 in	 the	 Protein	 Data	 Bank	 (PDB)	 (Berman	 et	 al.	 2000),	 almost	
100,000	have	been	 solved	using	X-ray	 crystallography	 compared	 to	11,000	
by	NMR,	the	second	largest	contributor.	It	has	been	stated	that	“structure	is	
function”	 and	 research	 into	 a	 protein’s	 3D	 structure	 often	 underpins	 and	
gives	 insight	 into	 functional	 mechanisms.	 The	 crystallographic	 structures	
provide	 a	 useful	 model	 for	 the	 rational	 development	 of	 drugs	 through	
visualisation	of	the	binding	environment	which	can	inform	further	rounds	of	
chemical	 alteration.	 As	 X-ray	 crystallography	 has	 been	 extensively	 used	 in	
this	 work,	 a	 brief	 summary	 of	 the	 technique,	 its	 development	 and	 basic	
principles	 are	 included	 in	 this	 chapter.	 The	 extensive	 details	 of	




	 Crystals	 have	 been	 produced	 since	 prehistory	 but	 the	 first	 recorded	
protein	crystals	were	produced	in	1840	by	Friedrich	Hünfield	of	earthworm	
haemoglobin.	 It	wasn’t	until	 the	discovery	of	X-rays	by	W.	Röntgen	 in	1895	
(Rontgen	1896)	and	subsequent	work	by	Max	Von	Laue	and	both	W.	H.	Bragg	
and	 W.	 L.	 Bragg	 (Bragg	 1913;	 Von	 Laue	 1913)	 into	 the	 nature	 of	 X-ray	
diffraction	 by	 crystals,	 that	 the	 idea	 of	 structural	 determination	 by	
crystallography	became	a	reality.	As	a	result	of	 this,	many	 inorganic	crystal	
structures	were	determined.	Whilst	work	into	inorganic	materials	continued,	
protein	 crystals	 began	 to	 be	 produced	 in	 earnest;	 the	 first	 enzyme	 to	 be	






This	 began	 an	 era	 of	 structural	 biology	 dominated	 by	 X-ray	
crystallography.	 David	 Phillips	 solved	 the	 structure	 of	 the	 first	 enzyme,	
lysozyme,	 in	 1965	 (Blake	 et	 al.	 1965).	 This	 provided	 the	 first	 structural	
insight	 into	 the	 functional	 mechanism	 of	 an	 enzyme.	 In	 1968	 the	 first	
structure	 of	 a	 human	 immunoglobin	was	 solved,	which	would	 later	 have	 a	
huge	 impact	 on	 modern	 pharmaceuticals	 (Waxdal	 et	 al.	 1968).	 Progress	
continually	 accelerated	 and	 new	 methods	 for	 crystal	 growth,	 X-ray	
generation	 and	 data	 collection	 were	 developed.	 The	 dawn	 of	 recombinant	
technologies	 allowed	 large	 quantities	 of	 proteins	 to	 be	 produced	 with	
relative	 ease	 and	 allowed	 crystallisation	 to	 be	 attempted	 on	 new,	
significantly	more	complex	targets.	Dedicated	synchrotron	light	sources	were	
opened	 to	 provide	 users	 with	 increasingly	 bright	 X-rays.	 The	 first	 such	
source,	 the	Synchrotron	Radiation	Source	 in	Daresbury,	opened	 in	1981.	 In	
1985,	 the	 first	membrane	 protein	 structure	was	 solved	 by	Hartmut	Michel	
and	 colleagues	 of	 the	 photosensitive	 reaction	 centre	 (Deisenhofer	 et	 al.	




Progress	 has	 continued	 and	 the	 accomplishments	 of	 protein	
crystallography	have	recently	been	celebrated	during	the	International	Year	
of	Crystallography	 last	 year	 (2014)	 and	 the	 International	Year	of	 Light	 this	
year	(2015).	Further	improvements	to	hardware,	including	third	generation	
synchrotrons	 (Helliwell	 &	 Mitchell	 2015;	 Duke	 &	 Johnson	 2010),	 and	 the	
development	 of	 the	 X-ray	 Free	 Election	 Laser	 (XFEL)	 (Cohen	 et	 al.	 2014;	
McNeil	 &	 Thompson	 2010;	 Neutze	 et	 al.	 2004;	 Fromme	 &	 Spence	 2011),	
which	produces	X-rays	of	brightness	 that	has	not	been	achieved	before,	are	
propelling	the	field	forward	and	maintaining	its	near	monopoly	in	the	study	
of	 protein	 structure.	 These	 structures,	 that	 would	 have	 previously	 been	
impossible	 to	 solve,	 are	 being	 produced	 using	 new	 techniques	 and	 more	












Protein	 crystallisation	 is	 a	process	of	 precipitation	by	which	protein	
leaves	a	solution,	first	by	nucleation	and	then	by	crystal	growth	(Figure	2.2a).	
Multiple	methods	have	been	used	and	developed	in	order	to	produce	protein	
crystals	 but	 they	 all	 follow	 the	 same	 principle:	 a	 slow	 increase	 in	 protein	
concentration	until	supersaturation	is	reached	allowing	stable	nucleation	to	
occur,	 followed	 by	 growth	 (McPherson	 1985).	 The	 crystals	 used	 in	 this	
project	 were	 all	 produced	 using	 vapour	 diffusion	 in	 either	 the	 sitting	 or	
hanging	drop	procedure	(Figure	2.2b,	c).	The	advent	of	HTP	crystal	screening	
robots	 and	 crystal	 viewing	hotels	has	made	 this	process	more	amenable	 to	
even	 the	 most	 difficult	 targets	 (Wasserman	 et	 al.	 2012;	 Heinemann	 et	 al.	
2001;	 O’Reilly	 et	 al.	 2006;	 Blundell	 et	 al.	 2002).	 Modern	 laboratories	 can	
screen	 a	 protein	 solution	 against	 thousands	 of	 precipitant	 conditions	 using	
very	 small	 amounts	 of	 sample	 (Li	 et	 al.	 2012;	 Stock	 et	 al.	 2005;	 Zhu	 et	 al.	
2014).	
	
Membrane	 protein	 crystallisation	 follows	 the	 same	 principles	 as	 the	
crystallisation	of	a	soluble	protein.	There	are	however,	additional	issues.	The	
inherent	 hydrophobicity	 of	 membrane	 proteins	 requires	 the	 addition	 of	
detergent	 for	 extraction	 from	 a	 lipid	 bilayer	 and	 further	 purification	
(Carpenter	 et	 al.	 2008;	 Michel	 1983).	 The	 detergent	 micelle	 that	 forms	
around	the	hydrophobic	region	of	the	protein	often	prevents	many	protein-
protein	 contacts	 from	 forming,	 which	 may	 result	 in	 weak	 diffraction	 or	
possibly	 prevent	 crystallisation	 from	 taking	 place.	 There	 are	 numerous	




to	 take	 place	 in	 a	 more	 native-like	 environment	 (Figure	 2.2d)	 (Landau	 &	
Rosenbursch	1996;	Caffrey	&	Cherezov	2009;	Cherezov	et	al.	2001).	This	has	
been	 used	 in	 the	 successful	 crystallisation	 of	 several	 novel	 drug	 targets	
(Cherezov	 et	 al.	 2010).	Membrane	protein	 crystals	 from	 the	 same	drop	are	





Figure	 2.2	 |	 The	 crystallisation	 of	 proteins.	 a	 A	 phase	 diagram	 depicting	 crystal	
nucleation	and	growth.	The	aim	is	to	move	the	conditions	into	the	nucleation	zone	and	
then	allow	crystal	growth	within	the	metastable	zone.	b	and	c	A	schematic	diagram	of	
the	 hanging	 drop	 vapour	 diffusion	 and	 sitting	 drop	 vapour	 diffusion	 techniques	 for	
crystal	 growth.	A	 drop	 of	protein	 solution	 is	mixed	with	precipitant	 solution	 from	 the	
well	resulting	in	a	drop	of	half	the	precipitant	concentration.	Vapour	then	diffuses	out	of	
the	drop	along	a	concentration	gradient	slowly	increasing	the	concentration	of	protein.	
The	 wells	 are	 sealed	 with	 cover	 slides	 and	 grease	 to	 create	 a	 nearly	 totally	 closed	
environment.	d	 An	 example	 of	 lipidic	 cubic	 phase	 (LCP)	 crystallisation	 in	 a	 sandwich	





When	 placed	 in	 an	 X-ray	 beam,	 a	 crystal	 will	 produce	 a	 pattern	 of	
discrete	spots;	a	diffraction	pattern.	The	incoming	X-ray	beam	is	scattered	by	
successive	 planes	 within	 the	 crystals.	 If	 these	 planes	 are	 suitably	 spaced,	
constructive	interference	between	the	scattered	waves	takes	place	producing	




𝑛𝜆 = 2𝑑 sin𝜃	
	
	Through	precession	imaging	a	crystal	is	rotated	within	the	incoming	
beam	 allowing	 precise	 degrees	 of	 data	 to	 be	 collected	 and	 reflections	




𝐹 𝑺 =  𝐹 𝑺 𝑒!"(𝑺)	
	
The	 intensities	 of	 each	 structure	 factor	 can	 be	 recorded	 and	 are	
directly	proportiona	l	to	the	square	of	the	magnitude	of	each	structure	factor.		
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The	phase	of	 the	structure	 factor	contains	vital	 information	required	
to	 produce	 an	 electron	 density	 map.	 This	 is	 effectively	 demonstrated	 by	
Cowtan’s	 example	 of	 the	 Duck	 and	 Cat	 (Taylor	 2010;	 Rupp	 2009).	 In	 this	
example	 the	magnitudes	 of	 a	 Fourier	 transformed	duck	 are	 combined	with	
the	phases	from	a	Fourier	transformed	cat.	The	reconstruction	of	the	image	
using	 these	 combined	 inputs	 results	 in	 the	 image	 of	 a	 cat.	 As	 the	 phase	
information	is	not	recorded,	it	must	be	determined	by	other	means.	Multiple	
methods	have	been	developed	 and	used	 to	 solve	 the	 structures	 of	 proteins	





Figure	 2.3	 |	 A	 schematic	 view	 to	 describe	 Bragg	 diffraction.	 To	 produce	
constructive	 interference	 of	 the	 resulting	 scattered	wave,	 the	 additional	 distance	




Max	 Perutz	 and	 John	 Kendrew	 were	 the	 first	 to	 show	 that	 protein	
crystals	 could	 be	modified	 by	 the	 attachment	 of	 “heavy”	 atoms	 to	 produce	
isomorphous	 heavy	 atom	 derivatives.	 This	 was	 first	 done	 on	 haemoglobin	
and	was	 later	 used	 to	 solve	 the	 structure	 of	myoglobin	 (Green	 et	 al.	 1954;	
Kendrew	et	al.	1958).	The	resulting	diffraction	of	 these	derivatives	produce	
diffraction	patterns	with	altered	 intensity	of	 the	resulting	reflections.	These	





Multi-wavelength	Anomalous	Diffraction	 (MAD)	 also	 relies	 on	 heavy	
atom	derivatives.	There	are	many	methods	that	can	be	used	to	produce	these	
derivatives	 of	 the	 protein	 crystals	 (Garman	 &	 James	 2003)	 and	 by	 using	
recombinant	 technologies	 it	 is	 possible	 to	 incorporate	 selenium	 atoms	
directly	 into	 the	structure	of	 the	protein	of	 interest	using	selenocysteine	or	
selenomethionine.	 MAD	 experiments	 can	 then	 be	 carried	 out	 on	 selenium	






The	 resulting	 anomalous	 signal	 often	 very	 small	 and	 so	 require	 accurate	
measurements	to	produce	a	result.	
	
Single-wavelength	 Anomalous	 Diffraction	 (SAD)	 uses	 the	 same	
principle	as	MAD	but	only	a	single	dataset	is	collected	at	the	absorption	peak.	
This	was	 first	 demonstrated	 in	 1981	 (Hendrickson	&	 Teeter	 1981).	 SAD	 is	
advantageous	 as	 the	 collection	 of	 one	 dataset	 is	 less	 damaging	 to	 crystals	
than	 the	 multiple	 datasets	 required	 by	 MAD	 due	 to	 less	 X-ray	 exposure.	
Protein	crystal	structures	have	previously	been	solved	using	the	anomalous	
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signal	 from	 sulphur	 atoms	 (Dauter	 et	 al.	 1999).	 Sulphur-SAD	 poses	
difficulties	due	 to	 the	 small	 amount	of	 anomalous	 signal	 the	 sulphur	atoms	
produce.	 A	 novel	 protein	 crystallography	 beamline	 has	 been	 developed	 at	





years	 thanks	 to	 the	 wealth	 of	 protein	 structures	 present	 in	 the	 PDB	
(Rossmann	2001).	Approximately	 two	 thirds	 of	 the	 structures	deposited	 in	
the	PDB	have	been	solved	by	MR	(Vagin	&	Teplyakov	2010).	MR	requires	an	
initial	 homology	model	 that	 should	 have	 a	 similar	 overall	 structure	 to	 the	
crystallised	 protein;	 usually	 a	 model	 with	 greater	 than	 30	 %	 sequence	
identity	 is	suitable.	The	model	 is	used	to	produce	a	Patterson	map	which	 is	
then	rotated	and	translated	against	the	Patterson	map	of	the	crystallographic	






Under	 bombardment	 from	 X-rays,	 protein	 crystals	 can	 become	
damaged	 (Garman	 2010).	 This	 radiation	 damage	 can	 take	 many	 forms	
including	reduction	of	prosthetic	groups,	reduction	of	disulphide	bonds,	loss	
of	resolution,	increased	mosaicity	(a	measure	of	disorder	between	unit	cells	
within	 the	 crystal	 lattice)	 and	 damage	 to	 the	 polypeptide	 chain.	 The	 vast	
majority	of	crystallography	experiments	are	now	carried	out	with	the	crystal	








in	 house	 or	 at	 synchrotron	 facilities.	 The	 majority	 of	 in	 house	 X-rays	 are	
produced	by	bombarding	a	rotating	metal	anode	with	high	voltage	electrons	
accelerated	 through	 an	 electric	 field.	 One	 such	 instrument	 is	 the	 FRE+	 by	
Rigaku	 currently	 used	 in	 the	 Barkla	 X-ray	 laboratory	 of	 biophysics	 at	 the	





anode	 X-ray	 generator.	 Electrons	 are	 released	 from	 a	 heated	 filament	 cathode	 that	
strike	 the	 rotating	 copper	anode	and	cause	 the	emission	of	X-rays.	These	X-rays	 can	
then	 be	 focussed	 and	 targeted	 on	 to	 a	 crystal	 sample	 and	 the	 resulting	 diffraction	
pattern	is	recorded	on	a	detector.	inset	A	photograph	of	the	Barkla	X-ray	laboratory	of	
Biophysics	 at	 the	University	 of	Liverpool	demonstrating	 this	 set	 up.	b	 A	 view	of	 the	
principle	 components	 of	 a	 synchrotron	 light	 source.	 Electrons	 are	 produced	 by	 an	
electron	gun	and	initially	accelerated	in	the	linear	accelerator	(LINAC).	These	electrons	
are	 then	 further	 accelerated	 in	 the	 booster	 ring	 to	 near	 the	 speed	 of	 light	 before	





rays	 at	 a	 wavelength	 1.54	 Å	 and	molybdenum	 emits	 X-rays	 of	 wavelength	
0.71	 Å.	 Both	 of	 these	 wavelengths	 are	 suitable	 for	 the	 study	 of	 atomic	




The	 broad	 spectrum	 of	 light,	 ranging	 from	 infrared	 to	 hard	 X-rays,	
emitted	 by	 charged	 particles	 under	 radial	 acceleration	 is	 referred	 to	 as	
synchrotron	 radiation	 (Figure	 2.4b).	 Synchrotron	 radiation	 is	 used	 to	






beamlines	 such	 as	 that	 at	 the	 SRS,	 Daresbury,	 UK	 in	 1981	 (Helliwell	 et	 al.	
1982).	Modern	synchrotrons	 such	as	Soleil,	Paris,	France	or	Diamond	Light	
Source	 (DLS),	 Oxfordshire,	 UK	 operate	 using	 the	 same	 principles	 as	 initial	





This	 increasing	 brightness	 results	 in	 an	 increased	 signal	 from	
diffraction	revealing	data	that	may	otherwise	not	been	detectable.	As	a	result	
of	 this,	 smaller	 crystals	 can	 now	 provide	 usable	 data	 despite	 their	 smaller	
diffracting	 volume.	 Small	 crystals	 can	 also	 be	 used	 due	 to	 the	 increasingly	
small	 beam	 sizes	 that	 are	 being	 produced	 (J.	 L.	 Smith	 et	 al.	 2012).	 A	 small	
beam	 size	 is	 also	 beneficial	 as	 it	 reduces	 the	 radiation	 damage	 across	 the	












	 Diffraction	 data	 are	 reduced	 by	 indexing	 using	 software	 such	 as	
HKL2000	 (Otwinowski	 &	Minor	 1997)	 or	 iMosflm	 (Leslie	 &	 Powell	 2007).	
The	 process	 of	 indexing	 	 records	 all	 reflections	 according	 to	 their	 Miller	
indices	(hkl),	 their	 intensity	(Ihkl)	and	 the	background	around	the	reflection	
(σIhkl).	 Multiple	 intensities	 of	 the	 same	 reflection	 are	 repeatedly	 collected	
during	data	collection.	These	intensities	often	vary	from	one	to	another.	This	
can	 be	 as	 a	 result	 of	 radiation	 damage,	 varying	 incident	 beam	 intensity	 or	
differences	 in	 absorption	 due	 to	 the	 thickness	 of	 the	 crystal.	 For	 these	
reasons,	 the	 reflections	 with	 the	 same	 index	 are	 scaled	 to	 one	 another	 to	
ensure	 the	 same	 intensity	 throughout	 the	 data.	 Data	 from	 multiple	






the	 observed	 amplitudes	 (|f(S)|obs)	 provide	 a	 starting	 point	 for	 refinement,	
which	can	then	be	used	to	create	an	initial	electron	density	map.	
	
𝜌 𝑟 =  𝑓(𝑆)𝑒!!!!".!𝑑S = 𝑓 𝑆 !"#𝑒!"#$%#(!)𝑒!!!!".!𝑑S 	
	
	 After	 the	 production	 of	 this	 initial	 map,	 rounds	 of	 automated	
refinement	 followed	by	manual	model	building	can	be	carried	out	 to	adjust	
the	atomic	model	 to	 improve	 the	 fit	 to	 the	diffraction	data.	As	 the	model	 is	
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refined,	 the	 calculated	 phases	 are	 improved	 which	 then	 allow	 for	 more	
alterations	to	the	model	to	fit	the	produced	electron	density.	To	ensure	that	
through	 these	 iterations	 of	 improvement	 the	 model	 comes	 to	 better	




























Cytochrome	 bc1	 (cyt.	 bc1),	 also	 known	 as	 Complex	 III	 or	 ubiquinol-
cytochrome	c	oxidoreductase	(E.C.	1.10.2.2),	is	a	homodimeric	multi-subunit	
integral	membrane	protein	found	within	the	inner	mitochondrial	membrane	
(IMM)	 (Figure	 3.1a).	 In	 eukaryotes,	 each	 monomer	 consists	 of	 10	 or	 11	
subunits	 depending	 on	 the	 species	 of	 origin	 (Table	 3.1).	 There	 are	 three	











Core	complex	I	 Matrix	side	 446	 	
Core	complex	II	 Matrix	side	 439	 	
Cytochrome	b	 8	TM	helices	 379	 Oxidation	 and	 reduction	
of	 ubiquinol/ubiquinone	
and	electron	transfer	





Subunit	6	 Matrix	 111	 	





Subunit	9	 Matrix	 78	 	
Subunit	10	 1	TM	helix	 62	 	





Figure	3.1	 |	The	structure	of	cytochrome	bc1	and	 its	 role	 in	 the	electron	transport	
chain	(ETC).	a	A	cartoon	cutaway	view	of	cyt.	bc1.	The	homodimer	is	integral	across	
the	 inner-mitochondrial	membrane	with	 the	 core	 proteins	 forming	 a	 large	 soluble	
portion	within	 the	matrix	and	the	soluble	domains	of	 cytochrome	c	and	the	Rieske	
iron-sulphur	protein	in	the	intermembrane	space.	b	A	schematic	view	of	the	ETC.	As	
electrons	 are	 passed	 along	 the	 chain,	 H+	 are	 transported	 into	 the	 intermembrane	
space	 creating	 a	 chemiosmotic	 membrane	 potential.	 Complex	 I	 is	 absent	 in	 many	
organisms	 including	 apicomplexa	 parasites	 and	 is	 replaced	 with	 a	 type	 II	 NADH	
dehydrogenase	which	does	not	act	to	pump	H+.	The	PDB	models	1nek,	1occ,	1ppj	and	




high	 redox	potential	heme	 (heme	bH).	Cyt.	c1	 contains	 a	 single	c-type	heme	
and	 the	 ISP	 contains	 an	 iron-sulphur	 cluster	 (2Fe-2S).	 The	 protein	 is	
functional	as	a	dimer,	as	the	transmembrane	region	of	the	ISP	passes	across	
cyt.	bc1	and	the	head	interacts	with	cyt.	b	and	cyt.	c1	of	the	adjacent	monomer.	
The	 flexibility	and	movement	of	 the	soluble	region	of	 the	 ISP	appears	 to	be	
essential	 for	 catalysis	 (Esser	 et	 al.	 2006;	Zhang	et	 al.	 1998).	The	 remaining	
supernumerary	subunits	appear	to	play	a	role	in	assembly	or	stability	of	the	
complex	(P.	M.	Smith	et	al.	2012).	The	production	of	the	full	protein	requires	
multiple	 chaperone	 proteins	 for	 both	 transport	 and	 assembly	 in	 the	
mitochondrial	membrane,	 and	 has	 been	 studied	 extensively	 in	 yeast	 (P.	M.	
Smith	et	al.	2012;	Zara	et	al.	2009).	The	two	largest	subunits	are	referred	to	
by	 the	misnomers,	 core	 1	 and	 core	 2,	 and	 are	 homologous	 to	 the	 α	 and	 β	
subunits	 of	 matrix	 processing	 peptidases	 (Silman	 et	 al.	 1967;	 Braun	 &	







Cyt.	 bc1	 is	 the	 third	 protein	 in	 the	 electron	 transport	 chain	 (ETC)	
located	 within	 the	 mitochondria	 (Figure	 3.1b).	 The	 ETC	 couples	 redox	
reactions	between	several	proteins	to	produce	a	membrane	potential	(ΔΨm)	
across	 the	 inner	mitochondrial	membrane.	Two	proton	donating	substrates	
are	 required	 from	 previous	 reactions	 for	 the	 ETC,	 reduced	 nicotinamide	
adenine	 dinucleotide	 (NADH)	 and	 flavin	 adenine	 dinucleotide	 (FADH2),	
which	 are	 produced	 by	 glycolysis	 in	 the	 cytosol	 and	 the	 citric	 acid	 cycle	
(Krebs	cycle)	in	the	matrix.	NADH	is	used	as	a	substrate	by	NADH:ubiquinone	
oxidoreductase	 (Complex	 I)	 transferring	 H+	 into	 the	 intermembrane	 space	
(IMS)	partially	producing	 the	ΔΨm	 and	reducing	ubiquinone	 to	ubiquinol	 in	
the	 process.	 FADH2	 is	 oxidised	 by	 succinate	 dehydrogenase	 (Complex	 II)	
producing	more	reduced	ubiquinol.	Ubiquinol	is	used	as	the	substrate	for	cyt.	
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bc1	 as	 per	 the	 modified	 Q-cycle	 (see	 section	 3.1.2)	 and	 results	 in	 the	
translocation	 of	 more	 H+	 and	 the	 reduction	 of	 cyt.	 c.	 Complex	 IV	 is	 the	
terminus	 of	 the	 ETC	 and	 oxidises	 cyt.	 c	 to	 reduce	 molecular	 oxygen,	
producing	water,	whilst	 translocating	more	H+	across	 the	 IMM	and	 into	 the	
IMS.	 The	 formation	 of	 supercomplexes	 between	 the	 ETC	 complexes	 have	
been	 detected	 and	 several	 have	 been	 isolated,	 studied	 or	 visualised	 using	
electron	microscopy	(Althoff	et	al.	2011;	Dudkina	et	al.	2010;	Winge	2012).	In	
several	 species,	 including	 S.	 cerevisiae	 and	 Plasmodium	 spp.,	 complex	 I	 is	
absent	 and	 is	 instead	 replaced	 with	 a	 non	 proton	 translocating	 Type	 II	
NADH:quinone	 oxidoreductase.	 The	 resulting	ΔΨm	 is	 essential	 for	 multiple	




The	 protonmotive	 Q-cycle	 was	 first	 proposed	 in	 1976	 by	 the	
biochemist	 Peter	 D.	 Mitchell	 to	 describe	 how	 cyt.	 bc1	 both	 oxidises	 and	
reduces	ubiquinol	and	ubiquinone	whilst	acting	as	a	proton	pump	(Mitchell	
1976).	This	work	contributed	to	him	receiving	the	Nobel	Prize	for	Chemistry	
in	 1978.	 It	 has	 since	 been	 altered	 and	 is	 now	 known	 as	 the	 “modified	





QH! + 2cyt 𝑐! + 2H!"#$%&!  ↔ 𝑄 + 2cyt 𝑐 + 4H!"#! 	
	
Two	 ubiquinol	 molecules	 are	 required	 for	 each	 complete	 reaction.	 Upon	
binding	 the	 Qo	 site,	 ubiquinol	 is	 oxidised	 and	 simultaneously	 reduces	 both	
the	2Fe-2S	 cluster	 and	heme	bH	(Zhu	et	 al.	 2007).	The	 two	 resulting	H+	 are	
translocated	to	the	IMS.	A	conformational	change	in	the	ISP	then	allows	the	
electron	 from	 the	 2Fe-2S	 cluster	 to	 reduce	 cyt.	 c1	whilst	 the	 electron	 from	
heme	 bL	 is	 transferred	 to	 heme	 bH.	 Heme	 bH	 now	 reduces	 the	 bound	
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ubiquinone	 to	 a	 semi-ubiquinone	 intermediate	 in	 the	 Qi	 site	 whilst	 cyt.	 c1	
reduces	 a	 cyt.	 c	molecule	 in	 the	 IMS.	 Cyt.	 c	 freely	 diffuses	 away	whilst	 the	









into	 reduce	 cytochrome	 c.	 Heme	 bL	 reduces	 heme	 bH	 which	 in	 turn	 reduced	






The	 inhibition	 of	 cyt.	 bc1	 in	 P.	 falciparum	 causes	 the	 mitochondrial	
membrane	potential	to	collapse	(Srivastava	et	al.	1997).	This	collapse	affects	
multiple	downstream	metabolic	pathways	that	require	the	electron	transport	
chain	 and	 is	 lethal	 to	 the	 parasite.	 The	 pyrimidine	 biosynthesis	 pathway	
appears	 to	 be	 of	 particular	 importance	 as	 the	 parasite	 lacks	 the	 genes	 for	
pyrimidine	scavenging	and	it	therefore	relies	solely	on	de	novo	biosynthesis	
(Gardner	 et	 al.	 2002).	 Pyrimidine	 biosynthesis	 requires	 a	 constant	 pool	 of	
ubiquinone	that	is	stopped	when	the	ETC	is	inhibited	(Srivastava	et	al.	1997).	
The	mitochondria	 produces	 little	 ATP	 and	 lacks	 several	 genes	 required	 to	
encode	 ATP	 synthase	 (Fry	 et	 al.	 1990;	 Gardner	 et	 al.	 2002).	 The	 ETC	 in	
Plasmodium	 spp.	 has	 been	 suggested	 to	 exist	 solely	 for	 the	 purpose	 of	














Atovaquone	 (Figure	 3.3	 1)	 is	 a	 broad-spectrum	 antiprotozoal	
clinically	 approved	 for	 use	 in	 the	 treatment	 of	 malaria,	 toxoplasmosis,	
babesiosis	and	pneumocystis	pneumonia.	Atovaquone	is	the	result	of	rational	
design	 against	 the	 mitochondria	 (Gutteridge	 1989)	 and	 is	 the	 only	
hydroxynapthoquinone	 clinically	 approved.	 It	 inhibits	 the	P.	 falciparum	 cyt.	
	 51	
bc1	 complex	 at	 1000	 fold	 lower	 concentrations	 than	 that	 of	 rat	 and	 similar	
mammalian	 cyt.	 bc1	 complexes	 (Fry	 &	 Pudney	 1992).	 Upon	 binding	 it	
collapses	 the	 mitochondrial	 membrane	 potential	 (Srivastava	 et	 al.	 1997)	
killing	 the	parasite.	However,	 it	 suffers	 from	poor	bioavailability	due	 to	 it’s	
low	water	solubility	and	high	protein	binding	(Dressman	&	Reppas	2000).	
	
During	 its	 development,	 it	 was	 noted	 that	 recrudescence	 occurred	
with	high	frequency	due	to	single	point	mutations	in	cyt.	b	(Looasreesuwon	
et	 al.	 1999).	 For	 this	 reason	 several	 drugs	 were	 considered	 as	 a	 partner	
compound	 and	 proguanil	was	 found	 to	 act	 synergistically	with	 atovaquone	
(Canfield	 et	 al.	 1995).	 The	 resulting	 combination	was	 initially	marketed	 as	
Malarone™	 by	 GSK	 and	 made	 available	 in	 1998	 but	 the	 price	 of	 the	
combination	 treatment	 is	 prohibitive	 in	 developing	 countries.	 Malarone	 is	
favoured	as	a	highly	effective	prophylactic	treatment	with	low	levels	of	side	
effects	(Radioff	et	al.	1996)	accounting	for	half	of	antimalarial	prescriptions	
in	 the	 U.S.A	 (Barton	 et	 al.	 2010).	 Recently	 the	 patent	 owned	 by	 GSK	 has	
	
Figure	3.3	|	The	structures	of	atovaquone	and	several	4(1H)-pyridones.	The	4(1H)-









of	 protozoa	 (Siregar	 et	 al.	 2015).	 Recent	 crystallographic	 work	 and	 direct	
analysis	 on	 parasite	 enzymes	 have	 verified	 the	Qo	 site	 as	 the	 site	 of	 action	
(Birth	 et	 al.	 2014;	 Siregar	 et	 al.	 2015).	 The	Qo	 site	 is	 a	 relatively	 large	 and	
conserved	 domain	 formed	 by	 cyt.	b	 that	 shows	 a	 high	 degree	 of	 flexibility.	
The	Qo	site	contains	the	PEWY	motif	on	a	loop	located	on	the	IMS	side	of	cyt.	
bc1	 that	 is	 well	 conserved	 across	 phyla	 (Crofts	 et	 al.	 1999;	 Kao	 &	 Hunte	
2014).	 Qo	 site	 inhibitors	 can	 be	 categorised	 according	 to	 how	 they	 bind	






Despite	being	partnered	with	proguanil	 as	 a	 combination	 treatment,	
resistance	to	atovaquone	has	spread	rapidly	amongst	P.	falciparum	in	Africa.	
By	 far	 the	 most	 frequent	 mutations	 in	 vivo	 are	 Y268S	 and	 less	 frequently	
Y268N,	though	many	others	have	been	detected	in	vitro	including	M133I	and	
L271F	 (Korsinczky	 et	 al.	 2000;	 Syafruddin	 et	 al.	 1999).	 The	 Y268S	 point	
mutation	 reduces	 atovaquone	 inhibition	 by	 several	 orders	 of	 magnitude	
whilst	 also	 affecting	 the	 catalytic	 turnover	 of	 cyt.	 bc1	 (Fisher	 et	 al.	 2012;	
Korsinczky	et	al.	2000).	
	
The	 exact	 mechanism	 of	 proguanil	 synergy	 is	 unknown.	 When	
administered	 as	 a	 monotherapy,	 proguanil	 is	 processed	 into	 cycloguanil,	 a	
DHFR	 inhibitor.	 When	 administered	 in	 combination	 with	 atovaquone,	 it	
appears	 that	 the	 proguanil	 in	 its	 native	 form	 inhibits	 dihydroorotate	









the	 P.	 falciparum	 ETC	 (Painter	 et	 al.	 2010;	 Nixon,	 Pidathala,	 et	 al.	 2013;	
Stocks	 et	 al.	 2014).	 The	 Qo	 site	 of	 cyt.	 bc1	 is	 currently	 the	 most	 well	
characterised	 target	 of	 the	 ETC	 and	 several	 classes	 of	 drug	 have	 been	
developed	 against	 it.	 Atovaquone	 does	 not	 have	 ideal	 pharmaceutical	






The	 pyridones	 have	 been	 developed	 since	 continuing	 from	 work	 in	
1960’s	that	identified	the	antimalarial	affects	of	clopidol	(Markley	et	al.	1972)	
(Figure	 3.3	2)	 and	 that	 the	 effect	was	 on	 the	 ETC	within	 the	mitochondria	
(Fry	 &	 Williams	 1984).	 Clopidol	 has	 been	 shown	 to	 have	 activity	 against	
atovaquone	 resistant	 strains	 of	 P.	 falciparum,	 which	 led	 researchers	 to	
believe	 it	 bound	 in	 the	 Qo	 site	 in	 a	 novel	 manner	 (Barton	 et	 al.	 2010).	
Structure	 activity	 relationships	 (SARs)	 were	 carried	 out	 on	 a	 series	 of	
derivatives	 of	 clopidol	 modified	 on	 the	 hypothesis	 that	 it	 was	 acting	 as	 a	
ubiquinone	 antagonist.	 The	 addition	 of	 a	 lipophilic	 side	 chain	 and	 the	
halogenation	of	the	pyridone	group	at	position	3	increased	the	potency	of	the	
compound	 200	 fold	 compared	 to	 clopidol	 in	 vivo	 and	 1000	 fold	 in	 vitro	
(Yeates	et	al.	2008).	The	pyridone	group	has	also	been	extensively	modified	






and	 went	 through	 preclinical	 trials	 showing	 an	 apparent	 selectivity	 of	 P.	
falciparum	 cyt.	bc1	 over	 the	mammalian	 and	 a	 nanomolar	 IC50	(Xiang	 et	 al.	
2006).	 However,	 it	 had	 to	 be	 withdrawn	 due	 to	 histopathalogical	
complications,	 thought	 likely	 due	 to	 its	 high	 lipophilicity	 and	 non-linear	
dosage	 (Bueno	et	al.	2012).	GSK932121	(Figure	3.3	4)	was	developed	 from	
GW844520	by	the	addition	of	an	hydroxymethyl	at	C6	(Bueno	et	al.	2011).	It	
proved	 potent	 against	multi-drug	 resistant	P.	 falciparum	 in	 a	mouse	model	
(Jiménez-Díaz	 et	 al.	 2009)	 with	 improved	 bioavailability	 and	 was	 taken	
forward	to	phase	I	clinical	trials.	A	prodrug	(Figure	3.3	5)	was	developed	in	
parallel	 with	 the	 addition	 of	 a	 phosphate	 ester	 group	 and	was	 progressed	
into	 preclinical	 analysis.	 Acute	 toxicity	 was	 found	 when	 the	 prodrug	 was	
administered	 to	 rats,	 which	 was	 thought	 to	 be	 due	 to	 the	 inhibition	 of	




	 The	 antimalarial	 activity	 of	 quinolones	 as	 a	 class	 of	 inhibitors	 has	
been	known	since	work	done	on	endochin	(Figure	3.4	6)	 in	1948	and	their	
effect	 on	 toxoplasmosis	 since	1951	 (Gingrich	&	Darrow	1951).	 Initial	work	
on	these	compound	suffered	due	to	the	lack	of	suitable	biological	models	and	
knowledge	 of	 the	 parasite	 biochemistry.	 More	 recent	 work	 has	 led	 to	 the	
synthesis	 of	 a	 series	 of	 compounds	 known	 as	 endochin-like	 quinolones	
(ELQs)	(Winter	et	al.	2011).	These	compounds	have	been	shown	to	have	high	
IC50s	 but	 suffer	 from	 low	 solubility	 and	 bioavailability	 (Winter	 et	 al.	 2011;	
Winter	 et	 al.	 2009;	 Cross	 et	 al.	 2010).	 ELQs	 have	 been	 shown	 to	 impede	
parasite	growth	by	 inhibition	of	cyt.	bc1	and	affect	both	 the	 liver	and	blood	




	 Endochin	 was	 rapidly	 metabolised	 and	 so	 suffered	 from	 rapid	
clearance.	 The	 addition	 of	 a	 diphenylether	 functional	 group,	 from	 GSKs	
	 55	
4(1H)-pyridone	 program,	 in	 place	 of	 the	 lipid	 chain	 improved	 this	 and	
resulted	 in	 compounds	such	as	ELQ	271	and	ELQ	300	 (Figure	3.4	7	 and	8)	
(Nilsen	et	al.	2014).	ELQ	300	is	a	particularly	potent	antimalarial	that	shows	









to	be	 an	 effective	 antimalarial	 and	have	 a	mild	 effect	 on	 cysts	 formation	 in	




octyl	 aryl	 chain	 from	 endochin	 and	 subsequent	 replacement	 with	 the	 diphenyl	 ether	








	 The	bisaryl	 quinolones	were	developed	 from	a	program	designed	 to	
target	 the	P.	falciparum	NADH:ubiquinone	reductase	(PfNDH2)	(Pidathala	et	
al.	2012).	Many	of	the	compounds	tested	from	this	synthesis	possessed	IC50s	





The	 initial	 bisaryl	 compounds	 suffered	 from	 poor	 solubility	 and	 so	
further	 work	 was	 carried	 out,	 introducing	 heterocycles	 in	 to	 the	 aryl	 side	
chain	(Leung	et	al.	2012).	Several	of	 these	new	compounds	also	maintained	















site	 inhibitor	 and	 work	 on	 P.	 falciparum-like	 yeast	 appear	 to	 confirm	 this	





Acridines,	 acridones	 and	 acridinediones	 were	 initially	 investigated	
due	to	their	ability	to	bind	to	heme	and	prevent	biocrystallisation.	Several	of	
the	 compounds	 also	 inhibited	P.	 falciparum	 growth	 through	other	methods	
(Dorn	et	 al.	 1998).	They	were	 further	developed	 into	 acridinediones	which	
showed	 an	 affect	 on	 parasite	 O2	 consumption	 and	 cross-resistance	 with	
atovaquone	 (Suswam	 et	 al.	 2001).	 Work	 done	 at	 the	 Walter	 Reed	 Army	
Institute	 of	 Research	 resulted	 in	 compound	 WR	 249685	 (S	 enantiomer)	
(Figure	3.5	13)	which	was	shown	to	be	a	potent	inhibitor	(IC50	=	3	nM)	of	the	
parasite	 cyt.	 bc1	 Qo	 site	 and	 collapse	 the	 parasite	 membrane	 potential	
(Biagini	et	al.	2008).	
	
	 Acridone	compounds	were	studied	 for	 their	hemozoin	 inhibition	but	







Previous	 work	 studying	 the	 binding	 of	 both	 the	 pyridones	 and	
quinolones	 to	 cyt.	 bc1	 has	 been	 based	 on	 homology	 modelling,	 docking	 or	
mutation	studies.	These	methods	are	not	without	their	merit	but	can	provide	
unreliable	information.	No	work	has	previously	been	done	to	determine	how	
the	 compounds	 that	 are	 toxic	may	 bind	 and	 inhibit	mammalian	 cyt.	 bc1.	 A	
deeper	understanding	of	the	drug	binding	to	mammalian	cyt.	bc1.	when	used	
in	the	context	of	differences	between	mammalian	and	protozoan	complexes,	
could	 be	 used	 to	 inform	 further	 drug	 development.	 Ideally	 this	 would	
increase	 selectivity	whilst	maintaining	 efficacy	 against	 the	 parasite.	 In	 this	
work	 protein	 crystallography	 has	 been	 used	 to	 visualise	 the	 binding	 of	
antimalarial	compounds	to	bovine	cyt.	bc1.	Bovine	cyt.	bc1	has	been	used	as	a	
mammalian	model	due	to	its	high	sequence	identity	to	the	human	form	of	the	
protein	 (Figure	3.6).	Bovine	heart	 tissue	was	used	as	 it	 is	 relatively	easy	 to	


















and	 eluted	 along	 a	 gradient	 of	 150	 mM	 –	 350	 mM	 NaCl.	 This	 yielded	 an	
incomplete	 separation	 of	 cytochrome	 c	 oxidase	 from	 cyt.	 bc1.	 This	 was	
subsequently	modified	 in	 line	with	 other	 recorded	 purifications	 of	 cyt.	 bc1	
(Huang	 et	 al.	 2005)	 so	 that	 after	 the	 protein	 was	 loaded	 onto	 a	 column	
equilibrated	with	250	mM	NaCl,	it	was	eluted	along	a	gradient	of	250	mM	to	











Size	 exclusion	 chromatography	 was	 carried	 out	 on	 a	 HiPrep	 16/60	
Sephacryl	 S-300	 HR	 gel	 filtration	 column	 (GE	 Healthcare)	 and	 resulted	 in	
highly	 pure	 bovine	 cyt.	 bc1	 (Figure	 3.5b).	 Size	 exclusion	 helped	 to	 remove	
some	of	the	remaining	cyt.	bc1-cyt.	c	oxidase	complex	and	any	aggregates	that	
had	formed.	Ligands	were	added	after	gel	filtration	to	two-fold	molar	excess	





PEG	 fractionation	was	used	as	 a	 final	purification	 step	 in	 later	work	







shown	 in	 blue,	 415	 nm	 absorbance	 is	 shown	 in	 red.	 Fractions	 collected	 are	 indicated	
between	 the	 grey	 lines.	 a	 DEAE-sepharose	 removes	 the	 majority	 of	 the	 solubilised	
mitochondrial	proteins	as	flow	through	leaving	a	large	peak	of	cyt.	bc1	and	a	small	amount	
of	other	contaminants	including	residual	cytochrome	c	oxidase.	The	column	is	shown	being	
loaded	 with	 solubilised	 protein	 with	 cyt.	 bc1	 bound	 at	 the	 top.	 b	 Size-exclusion	
chromatography	on	a	Sephacryl-S300	gel	filtration	column	is	used	to	remove	the	majority	of	






Figure	 3.8	 |	 A	 typical	 result	 from	 PEG	 fractionation.	 Numbers	 indicate	 the	
relative	 volume	 of	 precipitant	 buffer	 added	 to	 cyt.	 bc1	 containing	 solution.	 a	















Mitochondria	 1680	 -	 -	 -	
Detergent	solubilised	
mitochondria	
946	 95	 100	%	 9	%	
DEAE-sepharose	 72	 62	 65	%	 86	%	
S300-sephacryl	 40	 38	 40	%	 94	%	




Crystallisation	 was	 initially	 highly	 irreproducible	 and	 inconsistent.	 Crystal	
screening	was	carried	out	around	known	conditions	(Iwata	et	al.	1998)	in	the	
hanging	 drop	 format	 and	 successful	 conditions	 were	 then	 replicated	 using	
large	 volume	 sitting	drops	 in	 an	 attempt	 to	 increase	 crystal	 size.	 Screening	
took	 placed	 across	 a	 pH	 range	 6	 –	 7.5	 	 and	 PEG4000	 concentrations	 was	
altered	from	5	%	to	14	%.	Micro-seeding	using	crystal	seeds	from	successful	
hits	helped	to	increase	reproducibility	in	initial	trays	by	providing	nuclei	for	
further	 crystal	 growth.	 The	 crystallographic	 structures	 presented	 in	 this	
work	are	all	from	the	space	group	P	65.	Screening	was	also	carried	out	using	
varying	 amounts	 of	 the	 detergent	 6-O-(N-Heptylcarbamoyl)-methyl-α-D-	
glucopyranoside	(HECAMEG),	glycerol,	DMSO,	varying	protein	concentration	





Attempts	 were	 made	 to	 reproduce	 the	 higher	 resolution	 P	 21	 21	 21	
crystal	 form	as	 reported	by	Huang	 et	 al	 (Huang	 et	 al.	 2005)	 but	 ultimately	
failed.	Several	crystals	were	grown	using	variations	around	the	condition	but	
when	 tested	 they	 belonged	 to	 the	 P	 65	 space	 group	 too.	 These	 conditions	
required	 an	 unusual	 1:0.9:0.1	 ratio	 of	 protein:resevoir:additive	 	 in	 the	
hanging	 drop.	 Screening	 was	 attempted	 with	 altered	 precipitant	
concentration	 (5-13	 %	 PEG3350)	 and	 a	 variety	 of	 protein	 concentrations	
(30-50	mg/ml).	
	
LCP	 crystallisation	 was	 also	 attempted	 with	 cyt.	 bc1.	 Protein	 was	
screened	 mixed	 using	 two	 different	 lipids,	 at	 two	 temperatures	 across	 14	







Crystals	were	 screened	 on	 the	 home	 source	 before	 transport	 to	 the	
synchrotron	 for	 further	 analysis.	 Using	 the	 home	 source,	 cryoprotectants	
such	 as	 glycerol,	 sucrose,	 DMSO,	 PEG400,	 paratone-N-oil	 and	 sodium	
malonate	were	 screened	and	attempts	were	made	 to	optimise	 for	use	with	
cyt.	 bc1	 crystals.	 A	maximum	 resolution	 of	 20	 Å	was	 observed	 for	 crystals	
using	PEG400	as	a	cryoprotectant	whilst	crystals	 in	sucrose,	paratone-N-oil	
and	malonate	 all	 failed	 to	 yield	 substantial	 diffraction.	 Glycerol	 and	 DMSO	






Figure	 3.9	 |	 Crystals	 hits	 using	 lipidic	 cubic	 phase	 cyt.	 bc1.	 All	 crystals	were	 grown	 in	
batch	with	monoolein	lipid	(MAG9.9).	a	Room	temperature	crystals	grown	with	0.001	M	
cadmium	 chloride/0.03	 M	 magnesium	 chloride,	 0.1	 M	 MES	 (pH	 6.5)	 and	 30	 %	 (v/v)	









failed	 to	 yield	 a	 crystallographic	 structure.	 Cyt.	 bc1	 formed	 crystals	 in	 the	
















crystals	 were	 grown	 at	 4	 °C	 with	 an	 initial	 protein	 concentration	 of	 30	 mg/ml.	 a	
Cytochrome	 bc1	 crystals	 with	 GW844520	 grown	 with	 10	 %	 PEG4000	 as	 a	 precipitant	







4)	 were	 grown	 to	 full	 size	 over	 the	 course	 of	 a	 week	 (Figure	 3.10).	 Data	
collection	 and	 refinement	 statistics	 are	 in	 Table	 3.3.	 No	 electron	 density	
peaks	were	present	in	the	Qo	site	of	cyt.	bc1	but	a	strong	positive	peak	in	the	
Fo-Fc	difference	map	was	visible	within	 the	Qi	 site	 for	both	GW844520	and	




Figure	 3.11	 |	 Binding	 of	 4(1H)-pyridones	 to	 bovine	 cytochrome	 bc1.	 a	 GW844520	
(orange)	bound	to	cyt.	bc1.	An	initial	Fo-Fc	map	contoured	at	3	σ	in	green	followed	by	the	















































transmembrane	 region	 of	 cytochrome	 b.	 It	 is	 accessible	 through	 a	






The	 head	 of	 the	 compound	 was	 unambiguously	 placed	 in	 plane	
according	 to	 the	 omit	 Fo-Fc	 density	 and	 oriented	 placing	 the	 amine	 of	 the	
pyridone	opposite	His201	and	Ser205	of	helix	D	(Figure	3.12).	The	carbonyl	
of	both	GW844520	and	GSK932121	are	positioned	within	3.5	Å	of	both	Ser35	
on	 loop	 A	 and	 OD1	 of	 Asp228	 on	 loop	 E	 which	 appears	 to	 be	 common	
amongst	 compounds	 that	 have	 been	 visualized	 within	 the	 Qi	 site.	 The	
chlorine	 atom	 at	 position	 3	 appears	 surrounded	 by	 aliphatic	 residues.	 The	
diphenyl	ether	tail	was	placed	in	to	the	density	directed	towards	Met190	and	
Met194.	 After	 refinement	 with	 the	 compounds	 added	 to	 the	 structure,	
additional	 electron	 density	 became	 visible	 allowing	 the	 positioning	 of	 the	





The	 additional	 hydroxyl	 group	 at	 position	 6	 on	 the	 head	 of	













Figure	 3.12	 |	View	of	 the	4(1H)-pyridones	overlaid	bound	 in	 the	Qi	 site	of	bovine	
cytochrome	bc1.	Atoms	are	colour	coded	accordingly:	oxygen	in	red,	nitrogen	in	blue,	
chlorine	 in	 green.	 Carbon	 atoms	 in	 cyt.	 b	 are	 grey,	 in	 GSK92121	 are	 cyan	 and	
GW844520	 is	displayed	as	orange.	a	The	pyridone	head	groups	of	GW844520	and	
GSK932121	 within	 the	 Qi	 site	 overlap	 entirely.	 The	 additional	 hydroxyl	moiety	 of	
GSK932121	is	positioned	near	His201.	b	Both	compounds	lie	along	helices	A	and	D	of	
cyt.	b	with	the	triflouromethyl	group	terminating	near	Met190	and	Met194.	The	first	















the	 binding	 site	 towards	 Ala23,	 Pro24	 and	 Ile27,	 and	 Trp31.	 It	 potentially	




between	 His201	 and	 Ser205.	 The	 tail	 extends	 outwards	 towards	 the	





in	 the	 hanging	 drop	 format.	 b	 Crystals	 grown	 using	 8	 %	 PEG4000	 in	 a	 hanging	 drop	
experiment	with	an	initial	protein	concentration	of	40	mg/ml.	Crystals	were	seen	as	large	as	
ca.	200	µm.	c	Proteins	grown	using	9	%	PEG3350.	Crystals	grew	as	rods	and	grew	to	ca.	100	






































	 In	 order	 to	 further	 improve	 the	 compounds	 discussed	 so	 far,	 it	 is	
necessary	to	understand	the	differences	between	the	mammalian	cyt.	bc1	and	
the	 cyt.	 bc1	 complexes	 of	 both	 P.	 falciparum	 and	 T.	 gondii.	 A	 sequence	
alignment	 was	 carried	 out	 on	 the	 protein	 sequences	 using	 ClustalOmega	
(Sievers	 et	 al.	 2011)	 (Figure	 3.16)	 and	 homology	 models	 were	 produced	
using	 the	 SWISS-MODEL	 server	 (Biasini	 et	 al.	 2014)	 (Figure	 3.17).	 The	
primary	sequence	alignment	shows	that	these	proteins	are	largely	conserved,	
but	 that	 there	 are	 several	 differences.	 The	 N-terminal	 sequence	 is	









Figure	 3.14	 |	Binding	of	MJM	170	within	 the	Qi	site.	Carbon	atoms	of	 cyt.	b	are	 coloured	
grey,	carbon	atoms	of	MJM170	are	coloured	purple.	a	The	Fo-Fc	difference	map	contoured	at	
3	σ	clearly	shows	the	location	of	MJM	170	within	the	Qi	site.	b	When	the	ligand	is	refined	in	















Figure	 3.16	 |	 Sequence	 alignment	 of	 mammalian	 and	 apicomplexa	 cytochrome	 b	 amino	 acids	
sequences.	 Key	 residues	 involved	 in	 the	 binding	 of	 4(1H)-pyridones	 and	 the	 tetrahydroquinolone	
MJM	170	in	the	Qi	site	are	identified	by	triangles.	There	are	several	differences	in	the	Qi	site	which	






The	homology	produced	models	 of	P.	 falciparum	 and	T.	gondii	 cyt.	b	
were	aligned	to	the	crystal	structure	of	bovine	cyt.	b	with	an	RMSD	0.649	and	









of	P.	falciparum	 cytochrome	b.	c	Model	of	T.	gondii	 cytochrome	b.	The	overall	structure	 is	similar	
differences	 in	 the	helix	a	of	the	N-terminus	can	be	seen.	The	helix	of	T.	gondii	 is	 far	shorter	 than	
those	 of	 bovine	 and	 P.	 falciparum	 (the	 bovine	 N-terminus	 could	 not	 be	 modelled	 into	 electron	
density	and	therefore	looks	shorter	than	it	may	be).	The	P.	falciparum	and	T.	gondii	models	appear	
to	have	larger	loops	than	the	bovine	towards	the	bottom	of	the	structure	which	could	affect	the	size	














These	 crystallographic	 studies	 show	 that	 both	 GW844520	 and	
GSK932121	 are	 Qi	 site	 inhibitors	 of	 the	 bovine	 cyt.	 bc1	 complex.	 This	 has	
revealed	the	mechanism	by	which	these	compounds	were	able	to	overcome	
atovaquone	 resistance	 in	 the	 Qo	 site.	 This	 is	 contrary	 to	 previous	 work	
suggesting	an	alternate	binding	mode	within	 the	Qo	 site	based	on	mutation	
and	 in	 silico	 studies	 (Rodrigues	 et	 al.	 2009).	 As	 stated	 previously,	 both	 of	
these	compounds	bind	in	a	very	similar	mode,	which	is	unsurprising	due	to	










binding	 of	 the	 compound,	 which	 may	 help	 develop	 novel	 compounds	 that	
bind	 the	 Qi	 of	 the	 parasite	 complex	 and	 not	 that	 of	 the	 host.	 Information	
about	 the	 role	 ordered	 water	 molecules	 play	 in	 the	 binding	 of	 the	 4(1H)-









network	 of	 H-bonds,	 which	 could	 help	 explain	 the	 additional	 efficacy	 of	
GSK932121	 compared	 to	 GW844520	 (IC50	 2	 nM	 compared	 to	 5	 nM	
respectively	 (Bueno	 et	 al.	 2012)).	 Both	 His201	 and	 Ser205	 are	 conserved	
residues	and	are	unlikely	to	alter	position	radically	in	either	parasites	cyt.	bc1	








these	 cells	 to	 mitochondrial	 inhibitors	 and	 reverses	 the	 Crabtree	 effect	











from	 the	 endochin-like	 quinolone	 scaffold	 with	 increased	 solubility	 and	
	
Figure	3.20	|	Effects	of	inhibitors	on	HEK92	cell	viability	when	grown	in	different	




grown	 on	 galactose	 but	 not	 when	 grown	 on	 glucose,	 confirming	 their	
mitochondrial	 inhibition	effect	on	human	cells.	e	and	f	ELQ300	and	SL-2-25	were	




already	 been	 carried	 out	which	 suggested	 that	MJM	170	was	 a	Qi	 inhibitor	
based	 on	 the	 4(1H)-pyridones	 using	 yeast	 mutations	 in	 the	 Qi	 site	 that	
prevented	MJM170	inhibition.	The	crystallographic	structure	provides	direct	
evidence	of	 this.	Due	 to	 the	 structural	 similarity	between	MJM	170	and	 the	
4(H)-pyridones,	its	binding	is	similar	within	the	Qi	site.	The	additional	ring	of	
MJM	170	is	positioned	further	towards	the	end	of	the	Qi	site	with	the	planar	
region	 occupying	 the	 same	 space	 as	 the	 pyridones	 (Figure	 3.16).	 The	
puckered	 ring	 is	 located	 in	 a	 hydrophobic	 region	 that	 shows	 variation	
between	 the	 mammalian,	 P.	 falciparum	 and	 T.	 gondii	 sequences	 and	 is	 a	
promising	region	for	 further	drug	development.	Ala23	 lies	at	 the	end	of	 the	
channel	 and	 is	 replaced	 by	 Cys13	 and	 Cys18	 in	P.	 falciparum	 and	T.	gondii	
respectively.	Met210	or	Leu214	substitutes	Tyr224,	which	is	placed	over	the	
ring.	 This	 will	 remove	 any	 stacking	 interaction	 that	 takes	 place	 in	 the	
protozoa	cyt.	b	but	remains	hydrophobic.	Trp26	is	replaced	by	a	Tyr	residue	
in	the	T.	gondii	protein,	this	could	potentially	open	the	Qi	site	up	towards	the	











Qo	 to	Qi	 site	 binding	 compounds	 (Stickles,	 Justino	 de	Almeida,	 et	 al.	 2015).	
This	 identified	several	 important	moieties	on	4(1H)-quinolone	scaffold	 that	







4(1H)-pyridones	 and	 4(1H)-quinolones	 against	 cyt.	 bc1	(Nilsen	 et	 al.	 2014;	
Yeates	 et	 al.	 2008).	 Helix	 a	 of	 the	 N-terminus	 forms	 a	 large	 number	 of	
hydrophobic	reactions	with	this	functional	group	and	is	largely	unconserved	
between	the	mammalian	and	parasites	forms.	Phe18	is	clearly	positioned	to	




Figure	 3.21	 |	 Conservation	 in	 the	 Qi	 site	 of	 cyt.	 b	 between	 parasite	 and	mammalian	
models.	The	 bovine	 structure	 is	 illustrated	with	 conserved	 residues	emphasised	using	







of	 these	 two	 residues	 maintains	 the	 hydrophobic	 interactions	 across	 the	
diphenylether	 in	 all	 compounds	 whilst	 also	 providing	 the	 possibility	 for	 a	
	
Figure	 3.22	 |	 Overlaid	 homology	 models	 of	 both	 apicomplexa	 cytochrome	 b	 protein	
over	the	bovine	cytochrome	b	structure.	Ligands	GW844520,	GSK932121	and	MJM	170	
are	 coloured	 in	 orange,	 cyan	 and	 magenta	 respectively.	 Bovine,	 P.	 falciparum	 and	 T.	
gondii	cytochrome	b	are	yellow,	purple	and	blue	each.	a	The	overlaid	models	around	the	




polar	 interaction	 with	 a	 histidine	 residue.	 This	 would	 improve	 compound	
specificity.	 Pyridines	 have	 previously	 been	 incorporated	 into	 the	 lipophilic	
tail	 during	 compound	 development	 but	 appeared	 less	 effective	 that	 their	
phenyl	equivalents	(Nilsen	et	al.	2014).	
	
	 Ser35,	 which	 is	 located	 in	 a	 hydrophilic	 pocket	 surrounding	 the	
carbonyl	group	of	both	the	pyridones	and	quinolones,	is	substituted	by	a	Phe	
residue	 in	 both	 the	 P.	 falciparum	 and	T.	 gondii	 homology	models.	 In	 these	
models,	 the	phenyl	 ring	of	Phe	appears	 to	move	away	 from	the	hydrophilic	
Asp	and	Asn	residues	in	that	region	and	has	moved	in	a	way	that	could	form	
stacking	 interactions	with	 the	diphenyl	 tail.	Towards	the	apex	of	 the	cavity,	
Leu21	and	Ala23	in	the	bovine	protein	are	replaced	by	Tyr	and	Cys	residues	
respectively.	 The	 change	 to	 a	 Cys	 residue	 brings	 the	 hydrophobic	
environment	 closer	 to	 the	 compounds.	 The	 thiol	 is	 located	 above	 the	
puckered	 ring	 of	 MJM	 170	 and	 towards	 the	 methyl	 group	 of	 both	 4(1H)-
pyridones.	The	change	 from	Leu21	 to	Tyr	 in	both	parasites	 leads	 to	a	 large	
structural	 change	 in	 the	 binding	 site	 and	 fills	 a	 small	 pocket	 around	 the	
amine.	The	hydroxyl	group	could	form	interactions	here.	Tyr224	is	replaced	
by	Met210	 in	T.	gondii	 and	Leu214	 in	P.	 falciparum.	 Both	of	 these	 residues	










The	 merozoite	 stage	 of	 Plasmodium	 spp.	 is	 covered	 in	 an	 abundance	 of	
surface	proteins	named	merozoite	 surface	proteins.	Many	of	 these	proteins	
are	 thought	 to	 have	 a	 role	 in	 the	 adhesion	 to,	 reorientation	 on	 and	 the	
invasion	of	red	blood	cells	and	undergo	tightly	regulated	processing	(Boyle	et	
al.	 2014).	 These	 surface	 proteins	 have	 been	 the	 subject	 of	 vaccine	
development	 research	and	have	been	shown	 to	be	 targeted	by	 the	 immune	
system	 upon	 infection	 (Fowkes	 et	 al.	 2010;	 Richards	 &	 Beeson	 2009).	
Antibodies	 targeting	 the	 merozoites	 are	 thought	 to	 function	 through	
opsonisation	 for	 phagocytosis	 by	 the	 body’s	 immune	 system	 (Bouharoun-




Work	 carried	 out	 by	 Cruz-Gallardo	 et	 al	 (Cruz-Gallardo	 et	 al.	 2013)	
demonstrated	 the	 therapeutic	 benefits	 of	 cupredoxins	 in	 culture	 with	 P.	
falciparum	parasites.	The	cupredoxins	were	studied	due	to	their	homology	to	
the	immunoglobin	fold.	Rusticyanin	was	the	stand-out	cupredoxin	tested	and	




with	 a	 19	 kDa	 fragment	 of	 Plasmodium	 yeoli	 merozoite	 surface	 protein	 1	
(MSP119).	Reduced	rusticyanin	bound	with	a	Kd	of	2	µM	whilst	 the	oxidised	
form	 binding	 was	 an	 order	 of	 magnitude	 weaker	 (Kd	 =	 25	 µM).	 Apo-





proteins	 found	 on	 Plasmodium	 spp.	 merozoites	 (Kadekoppala	 &	 Holder	
2010).	MSP1	has	been	shown	to	have	a	role	in	red	blood	cell	binding	by	the	
	 86	
merozoite	 in	 a	 protein-dependent	 manner	 as	 opposed	 to	 sialic	 acid	
dependent	 interactions	 (Urquiza	 et	 al.	 1996;	 Goel	 et	 al.	 2003).	 In	 P.	
falciparum	MSP1	is	expressed	as	a	ca.	200	kDa	polypeptide	precursor	during	
schizogony.	The	polypeptide	is	highly	polymorphous.	During	maturation,	the	
MSP1	 polypeptide	 is	 processed	 into	 the	 mature	 protein	 through	 tightly	
controlled	cleavages.	The	mature	complex	remains	attached	to	the	merozoite	
surface	 by	 a	 glycosylphosphatidyl	 inositol	 (GPI)	 anchor	 on	 the	 C-terminus.	
MSP1	is	 initially	cleaved	into	four	polypeptides	which	remain	associated	on	
the	membrane	 of	 the	merozoites	 through	 non-covalent	 interactions	 during	
merozoite	release	(Figure	4.1).	The	first	cleavage	is	carried	out	by	the	serine	
protease	SUB1	(Koussis	et	al.	2009)	which	also	has	a	role	in	the	maturation	of	
MSP6,	 MSP7	 and	 AMA1.	 This	 cleavage	 results	 in	 4	 fragments:	 the	 largest	
fragment	is	an	the	N-terminal	83	kDa	fragment	MSP183,	two	more	fragments	
MSP130	 and	 MSP138,	 and	 the	 C	 terminal	 fragment	 MSP142.	 Without	 this	
cleavage,	merozoites	are	unable	to	invade	further	red	blood	cells	(Koussis	et	
al.	2009).	The	MSP1	complex	also	contains	protein	derived	from	the	surface	










Upon	 the	merozoite	 binding	 to	 a	RBC,	 a	 second	proteolytic	 cleavage	
step	 by	 membrane	 bound	 SUB2	 cleaves	 MSP142	 into	 MSP133	 and	 MSP119	
(Harris	et	al.	2005)	(Figure	4.1).	MSP133	is	a	soluble	protein	that	is	shed	from	
the	 membrane	 and	 blocks	 the	 inflammatory	 response	 mediated	 by	 S100P	
(Waisberg	et	al.	2012).	MSP119	remains	attached	to	the	cell	membrane	by	the	
GPI	 anchor	 and	 enters	 the	 red	 blood	 cell	 along	with	 the	merozoite	 (Figure	
4.2)	 (Blackman	 et	 al.	 1990).	 Antibodies	 targeting	 MSP142	 can	 prevent	 this	
proteolytic	cleavage	whilst	not	inhibiting	erythrocyte	invasion	(Blackman	et	
al.	1994).	MSP142	has	been	the	target	of	vaccine	candidates	that	have	entered	
clinical	 trials	 but	 there	 has	 not	 yet	 been	 great	 success	 (Ellis	 et	 al.	 2012).	




	 MSP119	 has	 been	 detected	 within	 the	 food	 vacuole	 of	 differentiated	
trophozoites	within	the	red	blood	cells	(Drew	et	al.	2005).	It	remains	on	the	
surface	 of	 the	 food	 vacuole	 without	 further	 modification	 and	 has	 been	
	









et	 al.	 2008).	 Antibodies	 targeting	 MSP119	 have	 been	 shown	 to	 prevent	
parasite	 growth	 and	 emphasize	 its	 importance	 in	 vaccine	 development	
against	malaria	(Egan	et	al.	1999).	Antibodies	bound	to	MSP119	may	also	be	
internalised	 upon	 red	 blood	 cell	 invasion	 (Blackman	 et	 al.	 1994).	 Recent	
work	 has	 targeted	 MSP119	 with	 small	 molecules	 that	 inhibit	 invasion	
(Chandramohanadas	et	al.	2014).	
	
MSP119	 is	 a	 well	 conserved	 protein	 across	 Plasmodium	 spp.	 and	 is	
formed	 by	 the	 cysteine	 rich	 C-terminal	 region	 of	 MSP1.	 Early	 sequence	
analysis	 indicated	 that	 structurally	 it	 consisted	 of	 two	 epidermal	 growth	
factor	(EGF)	like	domains	each	containing	six	cysteines	(Figure	4.3)	(Holder	
et	 al.	 1992;	O’Donnell	 et	 al.	 2000).	 This	 has	 since	 been	 confirmed	by	X-ray	
crystallographic	studies	in	complex	with	antibodies	and	NMR	in	solution	on	
its	own	(James	et	al.	2006;	Morgan	et	al.	1999;	Babon	et	al.	2007;	Garman	et	
al.	 2003).	 The	 96	 amino	 acid	 structure	 shows	 both	 EGF-like	 domains	
connected	 by	 a	 region	 of	 hydrophobic	 interactions	 (Morgan	 et	 al.	 1999).	
Likely	due	in	part	to	this	compact	structure	and	large	number	of	di-sulphide	
bonds,	MSP119	is	resistant	to	protease	degradation	which	has	been	suggested	
as	 one	 of	 the	 reasons	 it	 is	 able	 to	 remain	 present	 in	 the	 food	 vacuole	









against	 several	 diseases.	 These	 include	 HIV,	 cancers,	 toxoplasmosis	 and	





	 Rusticyanin	 is	 a	 particularly	 interesting	 cupredoxin.	 It	 has	 been	
isolated	 from	 the	 acidophilic	bacteria,	Thiobacillus	 ferroxidans,	 an	organism	
capable	 of	 growth	 using	 Fe2+	 as	 its	 only	 energy	 source	 (Ronk	 et	 al.	 1991).	
Rusticyanin	 has	 two	 remarkable	 properties.	 It	 has	 exceptionally	 high	 acid	
	
Figure	 4.3	 |	 Solution	 structure	 of	 MSP119.	 Cysteine	 residues	 involved	 in	
disulphides	 are	 drawn	 in	 purple	 sticks	 with	 sulphur	 atoms	 displayed	 as	
yellow	spheres.	a	 Side	view	of	MSP119	with	 the	membrane	 facing	die	at	 the	






cupredoxins	 which	 have	 more	 typical	 redox	 potentials	 of	 ca.	 300	 mV	
(Ingledew	&	Cobley	1980).	Its	seems	likely	that	these	properties	play	a	role	in	
the	 antimalarial	 properties	 reported.	 Structural	 studies	 of	 rusticyanin	 have	
been	 performed	 using	 both	 X-ray	 crystallography	 and	 NMR	 (Figure	 4.4)	
(Djebli	et	al.	1992;	Walter	et	al.	1996;	Kanbi	et	al.	2002;	Barrett	et	al.	2006;	




Figure	 4.4	 |	 Structure	of	 the	 cupredoxin	 rusticyanin.	The	Type	 I	 copper	
site	 residues	 are	 shown	 as	 sticks	 with	 a	 blue	 copper	 atom.	 A	 β-barrel	
sandwich	 lies	 at	 the	 core	 of	 the	 protein	 with	 2	 helices	 and	 regions	 of	









properties	 of	 rusticyanin	 provide	 it	 with	 the	 antimalarial	 properties	
described	 (Cruz-Gallardo	 et	 al.	 2013).	 These	 mutants	 provide	 an	 excellent	







and	 yielded	 a	 single	 protein	 peak	 of	 rusticyanin	 (Figure	 4.5).	 This	 showed	
that	there	was	no	need	for	gel	filtration	in	subsequent	work.	To	test	for	long-
term	storage,	protein	was	flash	frozen	in	liquid	nitrogen	with	or	without	the	















addition	 of	 10	 %	 glycerol.	 SEC	 revealed	 that	 the	 protein	 frozen	 with	 the	




	 Crystallisation	 was	 done	 according	 to	 previous	 crystallography	
reports	 (Djebli	 et	 al.	 1992)	 and	 produced	 large	 clusters	 of	 rusticyanin	
crystals	(Figure	4.6).	Previous	reports	of	the	native	protein	crystal	structure	
	
Figure	 4.5	 |	 Purification	 of	 rusticyanin.	 a	 Rusticyanin	 bound	 to	 SP-sepharose	
during	 the	 purification.	 b	 SEC	 purification	 of	 rusticyanin	 took	 place	 at	 room	
temperature	 and	 was	 easily	 tracked	 due	 to	 the	 distinct	 blue	 colour.	 c	 The	
chromatogram	 from	 rusticyanin	 SEC	 using	 Sephacryl	 200	 reveals	 a	 large	 single	
peak	after	SP-sepharose	purification	 indicating	no	need	for	repeating	 this	step	 in	
future	work.	 280	 nm	 absorbance	 is	 shown	 in	 blue,	 254	 nm	 in	 pink	 and	 592	 nm	
absorbance	in	red.	
	 93	
have	 been	 carried	 out	 at	 room	 temperature	 and	 data	 collected	 to	 1.27	 Å	
(Barrett	 et	 al.	 2006).	 A	 full	 dataset	was	 collected	 to	 1.1	 Å	 (Table	 4.2).	 The	
crystal	appeared	to	diffract	further	and	reflections	were	visible	to	0.9	Å	but	a	








the	 cell	 media	 through	 a	 secretion	 signal	 encoded	 in	 the	 plasmid	 pPIC9K	
(Invitrogen).	Selection	 for	multi-copy	 integrants	produced	a	strain	resistant	
to	0.75	mg/ml	G418-disulphide	 indicating	 the	presence	of	2-3	copies	of	 the	
MSP119	encoding	gene.	Expression	was	initially	carried	out	by	inducing	with	
0.5	%	methanol	 in	 BMMY	 but	 it	 was	 later	 found	 that	 0.1	%	 increased	 the	












































Rusticyanin	 was	 reduced	 using	 ascorbic	 acid	 to	 support	 binding	 to	
MSP119	 as	 reported	 (Cruz-Gallardo	 et	 al.	 2013).	When	 ran	 on	 gel	 filtration,	
the	oxidised	protein	did	not	appear	 to	 form	a	 complex	as	demonstrated	by	
the	two		distinct	peaks	(Figure	4.9	a).	MSP119	and	excess	reduced	rusticyanin	
were	 incubated	 prior	 SEC	 analysis	 and	 	 a	 small	 peak	 of	 potential	 protein	
complex	 eluted	 ahead	 of	 residual	 rusticyanin	 (Figure	 4.9	 b).	 The	 same	
quantity	 of	 rusticyanin	 was	 run	 as	 a	 control	 down	 the	 same	 column	 and	
yielded	 a	 single	 peak	 (Figure	4.9	c).	MSP119	 had	previously	 been	 shown	 to	
	
Figure	 4.7	 |	 High	 resolution	 electron	 density	 of	 rusticyanin.	 Water	 molecules	 are	
represented	by	red	spheres.	Copper	 is	represented	as	a	blue	sphere.	The	2Fo-Fc	electron	
density	map	 is	 drawn	 at	 1	 σ.	a	 The	N-terminal	 region	 of	 rusticyanin	 shows	 continuous	
density	but	 the	first	residue	Ala2	can	not	be	unambiguously	placed.	b	The	type	I	copper	






of	 rusticyanin	 could	 be	 due	 to	 complex	 formation.	 The	 presence	 of	 both	
rusticyanin	and	MSP119	were	confirmed	using	coomassie	stained	SDS-PAGE	




Figure	 4.8	 |	 Purification	 of	 P.	 falciparum	 MSP119.	 a	 Chromatogram	 of	 MSP119	 gel	
filtration.	280	nm	absorbance	shown	in	blue,	254	nm	absorbance	shown	in	red.	SEC	on	
Superdex	200	16/600	pg	column	revealed	a	single	peak	of	MSP119.	The	brackets	indicate	
the	 region	 collected	 for	 further	 work.	 b	 SDS-PAGE	 confirms	 the	 presence	 of	 MSP119	






formation.	 Blue	 line	 represents	 absorbance	 at	 280	 nm,	 the	 pink	 line	 represents	
absorbance	 at	 592	 nm.	a	 Oxidised	 rusticyanin	 and	MSP119	 run	 down	 a	 Sephacryl	 S75	
16/60	 gel	 filtration	 column	 separately	 resulting	 in	 a	 large	 peak	 of	 rusticyanin	 fist	
followed	by	a	small	peak	containing	MSP119.	b	Reduced	rusticyanin	added	to	excess	and	






Several	 commercial	 crystallisation	 screens	 were	 used	 across	 two	
concentrations	 of	 the	 protein	 complex.	 A	 crystallisation	 robot	was	 used	 to	











a	 Coomassie	 stained	 SDS-PAGE	 reveals	 rusticyanin	 presence.	 L1	 neb	 colour	 plus	
protein	 ladder,	 1	 rusticyanin	 control,	 2	 and	 3	 sample	 from	 rusticyanin	 peak	 in	
Figure	4.9b,	4	sample	from	shoulder	previous	to	rusticyanin	peak.	b	Western	blot	
using	an	anti-6xHis	antibody	confirms	the	presence	of	MSP119	in	the	complex	peak.	




did	 reach	a	higher	 resolution	 (visible	 spots	were	seen	 to	0.9	Å)	but	data	of	
reasonable	completeness	could	not	be	collected.		With	further	optimisation	of	




An	 excess	 of	 rusticyanin	 was	 added	 to	 MSP119	 in	 an	 attempt	 to	
produce	the	protein	complex.	Attempts	to	complex	P.	falciparum	MSP119	with	
both	oxidised	and	reduced	 rusticyanin	on	gel	 filtration	resulted	 in	differing	
absorbance	 profiles	 indicating	 complex	 formation	 is	 some	 how	 redox	
controlled.	This	would	further	explain	why	apo-rusticyanin	has	no	effect	on	
parasite	growth	 in	vivo	(Cruz-Gallardo	et	al.	2013).	Further	tests	need	to	be	






There	are	 currently	no	hits	 from	crystal	 trials.	Previous	examples	of	
antibodies	 that	have	been	co-crystallised	with	Plasmodium	knowlesi	MSP119	




a	 small	 amount	 of	 initial	 trays	 were	 set	 at	 low	 concentration.	 	 Further	
screening	 will	 take	 place	 and	 explore	 more	 conditions	 at	 a	 higher	
concentrations.	 Due	 to	 the	 need	 for	 reduced	 rusticyanin	 to	 form	 protein	













	 In	 this	work,	 the	 importance	of	structural	studies	 in	drug	design	has	
clearly	been	reiterated.	The	crystallographic	studies	carried	out	on	cyt.	bc1	in	
complex	with	 two	key	drug	classes	 in	 the	 search	of	novel	antimalarials	has	
revealed	 that	 the	 presumed	 site	 for	 binding	 was	 incorrect.	 This	 has	 also	
confirmed	 the	 reason	 for	 the	 failure	 of	 GSKs	 4(1H)-pyridones	 during	
development.	The	 identification	of	 the	Qi	 site	 as	 the	 site	of	 action	 for	 these	
compounds	will	 allow	 future	 antimalarial	 programs	 targeting	 cyt.	bc1	 to	 be	




	 Atovaquone	 is	 a	 successful	 prophylactic	 drug	 and	 has	 demonstrated	




have	 shown	 that	 resistance	 to	 endochin-like	 quinolones	 (ELQs)	 thought	 to	
target	the	Qi	site	are	less	prone	to	resistance	than	atovaquone	(Stickles,	Ting,	
et	al.	2015).	The	prospect	of	multiple	cyt.	b	targeting	compounds	in	a	medical	








Bovine	 cyt.	 bc1	 should	 continue	 to	 be	 used	 for	 research	 into	
antimalarial	 compounds	 that	 show	 signs	 of	 cross-species	 specificity.	 The	
large	 quantity	 of	 protein	 that	 can	 be	 readily	 purified	 and	 crystallised	 is	 of	
	 102	
great	 benefit	 to	 further	 studies.	 Crystallography	 has	 been	 used	 with	 great	
effect	 here	 to	 identify	 the	 correct	 binding	 mode	 of	 several	 potential	 next-
generation	drugs,	and	should	continue	to	be	used	for	this.	As	discussed	in	the	
body	 of	 this	 work,	 the	 insight	 gained	 from	 these	 structural	 studies	 can	
further	 instruct	drug	design	 to	prevent	binding	 to	 the	mammalian	 enzyme.	
Improved	 resolution	 should	 be	 attempted	 to	 increase	 our	 knowledge	 of	
binding	 within	 the	 Qi	 site	 of	 the	 current	 compounds	 which	 could	 identify	
more	precisely	 the	 importance	of	 various	 compound	 functional	 groups	 and	
elucidate	 the	 importance	 of	water	molecules,	 if	 any,	 for	 the	 binding	 of	 the	
next	generation	of	 compounds.	To	achieve	 this	 resolution,	work	 to	produce	
highly	 diffracting	 cyt.	 bc1	 crystals	 in	 the	 P	 21	 21	 21	 space	 group	 should	 be	








benefit	 from	 direct	 structural	 information	 from	 both	 of	 the	 parasite’s	
proteins.	Direct	visualisation	of	both	the	Qo	and	Qi	site	of	P.	falciparum	or	T.	
gondii	 cyt.	 b	 would	 reveal	 the	 exact	 binding	 mode	 of	 these	 anti-parasitic	
compounds	and	characterise	the	differences	in	structure	between	the	bovine	





process	 and	 the	 amount	 of	 protein	 that	 could	 be	 purified	 would	 be	 fairly	
small.	 However,	 thanks	 to	 the	 techniques	 developed	 whilst	 working	 on	




	 Another	 option	 for	 the	 further	 study	 and	 evaluation	 of	 these	
compounds	is	using	a	parasite	model.	Yeast	has	been	used	extensively	in	the	
production	of	P.	 falciparum	models	 for	 the	 study	of	 compound	binding	and	
resistance.	This	has	involved	a	series	of	mutations	within	cyt.	b	to	make	the	
binding	 sites	more	 parasite	 like	 (Vallières	 et	 al.	 2013).	 This	 is	 however	 an	
incomplete	 model.	 With	 the	 increased	 demonstration	 of	 genome	 editing	
techniques	 such	as	CRISPR/cas9	 (Dicarlo	 et	 al.	 2013)	 it	may	be	possible	 to	
switch	 entire	 subunits	 of	 cyt.	 bc1.	 This	 could	 be	 first	 attempted	 by	 simply	







	 Studies	 to	 determine	 mutation	 rates	 in	 the	 Qi	 site	 could	 provide	
further	 support	 for	 this	 site	 as	 a	 principle	 target	 in	 the	 development	 of	





been	 carried	 out.	 The	 purification	 of	 both	 rusticyanin	 and	 MSP119	 have	
successfully	 resulted	 in	 pure	 protein	 and	 initial	 attempts	 to	 produce	 the	
complex	have	been	attempted	on	gel	filtration.	Further	studies	on	this	native	
complex	will	 form	the	basis	 for	 future	work.	Crystal	screens	of	 the	complex	
have	not	yet	yielded	any	hits,	but	with	 time	and	more	 screening,	 it	may	be	












will	 also	 be	 amenable	 to	 crystallisation.	 This	 would	 elucidate	 the	 exact	
binding	 mode	 of	 the	 complex.	 Although	 no	 success	 has	 been	 seen	 from	
current	crystals	screens,	through	further	experiments,	it	may	prove	possible	
to	 produce	 diffracting	 crystals.	 In	 addition	 to	 X-ray	 crystallography,	 the	
complex	can	be	 further	probed	using	smalls	angle	X-ray	scattering	with	on-




	 The	 next	 stages	 of	 work	 will	 involve	 the	 production	 of	 various	
mutants,	 in	 order	 to	 alter	 their	 redox	 potential	 and	 acid	 stability.	 The	
complex	formed	between	these	proteins	to	MSP119	can	then	be	studied	using	
a	variety	of	biophysical	techniques	in	order	to	determine	how	these	altered	
properties	 vary	 the	 strength	 of	 the	 complex	 formed.	 The	 antimalarial	
properties	 of	 the	 mutants	 could	 then	 be	 studied	 in	 parasite	 culture.	 This	
would	 provide	 insight	 into	 the	 mechanism	 by	 which	 rusticyanin	 kills	




beneficial	 in	 the	development	 of	 treatments	 targeting	 toxoplasmosis.	 It	 has	
been	shown	that	azurins	bind	the	surface	protein	SAG1	(Surface	Antigen	1)	of	
T.	 gondii	 (Naguleswaran	 et	 al.	 2008).	 SAG1	 is	 also	 a	 GPI	 anchored	 surface	
protein	 that	 has	 been	 shown	 important	 for	 binding	 to	 host	 cells	 (Mineo	 &	
	 105	





With	 ongoing	 research	 into	 all	 avenues	 of	 malaria	 control	 there	 are	 a	
multitude	of	new	drugs	being	developed	with	a	variety	of	targets	(Wells	et	al.	
2015;	Burrows	et	al.	2013).	The	success	of	 the	recent	vaccine	development	
could	 assist	 in	 producing	 herd	 immunity	 amongst	 children	 in	 some	 of	 the	
worst	 affected	 places	 (RTS	 2015).	 Although	 generally	 asymptomatic,	 the	
long-term	 effects	 of	 toxoplasmosis	 are	 still	 relatively	 poorly	 understood.	
Patients	who	are	 immunocompromised	also	suffer	greatly	and	children	can	




site,	or	both	 the	Qo	an	Qi	 site	simultaneously,	 could	provide	a	novel	avenue	













Fatty	 tissue	 and	 connective	 tissue	 were	 removed	 from	 the	 heart	 using	 a	
sharp	 knife	 leaving	 behind	 cubes	 of	 lean	muscle	 tissue.	 Muscle	 tissue	 was	





added	 to	 a	 final	 concentration	 of	 0.1	mM.	 The	 solution	was	 centrifuged	 at	
1500	g	for	20	mins	at	4	°C	to	remove	remaining	tissue.	The	supernatant	was	









wash	 buffer	 2	 (50	 mM	 KPi	 (pH	 7.5),	 250	 mM	 NaCl,	 3	 mM	 NaN3,	 0.1	 mM	
PMSF).	 An	 aliquot	 was	 taken	 to	 determine	 protein	 concentration	 by	 BCA	
assay	 (Pierce,	 as	 per	 instructions)	 and	 the	 remainder	 of	 the	 solution	 was	




30	 mins.	 A	 colour	 change	 was	 visible	 if	 lysis	 occurred	 successfully.	 The	
solution	was	centrifuged	at	200,000	g	under	the	same	conditions	as	before.	
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along	 a	 gradient	 of	 250	 -	 500	 mM	 NaCl.	 Initial	 purification	 efforts	 were	
carried	 out	 on	 a	 gradient	 of	 150	 -	 350	 mM	 NaCl	 but	 yielded	 incomplete	
separation	of	cyt.	bc1	from	cytochrome	c	oxidase.	In	later	purification	efforts	






Fractions	 containing	 cyt.	 bc1	 were	 pooled	 from	 DEAE-sepharose	
purification	and	diluted	two-fold	with	50	mM	KPi,	3	mM	NaN3,	0.03	%	DDM	
and	 applied	 to	 a	 hydroxyapatite	 column	 ca.	 15	mL	 pre-equilibrated	 in	 the	
same	diluent	buffer.	The	bound	protein	was	washed	with	5	CV	before	eluting	





Protein	 from	 either	 DEAE-sepharose	 or	 hydroxyapatite	 was	
concentrated	to	ca.	500	µL	using	an	Amicon	Ultra-15	Centrifugal	filter	MWCO	
100	 kDa	 (Millipore).	 The	 concentrated	 solution	 was	 applied	 to	 a	 HiPrep	
Sephacryl-S300	HR	column	(ca.	120	ml)	pre-equilibrated	in	25	mM	KPi	(pH	
	 109	
7.5),	 100	mM	NaCl,	 3	mM	NaN3,	 0.015	%	DDM	and	 ran	 at	 0.5	ml/min.	The	
single	peak	containing	pure	homodimeric	cyt.	bc1	was	collected.	
	













precipitation	 buffer	 (100	 mM	 MES-KOH	 (pH	 6.4),	 0.5	 mM	 EDTA,	 10	 %	
PEG4000)	 relative	 to	 the	 protein	 solution	 volume	 as	 previously	 reported	
(Huang	et	al.	2005).	After	each	addition	of	precipitation	buffer,	 the	solution	
was	left	to	incubate	on	ice	for	20	mins	before	being	spun	at	13,000	g	at	4	°C.	
The	pellet	 of	precipitated	 cytochrome	bc1	was	 resuspended	 in	 gel	 filtration	
buffer.	 Fractions	 were	 analysed	 by	 SDS-PAGE	 for	 their	 purity	 and	 then	
combined.	The	resulting	solution	was	buffer	exchanged	into	25	mM	KPi	(pH	
7.5),	0.01	%	DDM,	3	mM	NaN3	or	20	mM	Tris-HCl	(pH	7.5)	,	0.5	mM	EDTA,	0.1	
%	 Undecyl	 β -D-maltoside	 (UM)	 (Generon)	 with	 an	 Amicon	 Ultra-15	
Centrifugal	 filter	 MWCO	 100	 kDa	 (Millipore)	 prior	 to	 crystallisation.	 Final	





Cyt.	 bc1	 was	 diluted	 in	 assay	 buffer	 (50	 mM	 KPi	 (pH	 7.5),	 0.5	 mM	
EDTA)	 and	 absorbance	was	 recorded	 at	 280	nm	and	415	nm	 to	 determine	
purity.	 The	 sample	 was	 the	 fully	 oxidised	 by	 the	 addition	 of	 potassium	
ferricyanide	crystals	and	the	absorbance	was	measured	at	562	nm	and	575	
nm.	 The	 same	 sample	 was	 then	 fully	 reduced	 using	 powdered	 sodium	
dithionite	 and	 the	 absorbance	 at	 562	 nm	 and	 575	nm	was	 recorded	 again.	
Using	 the	 sodium	 dithionite	 reduced	minus	 ferricyanide	 oxidised	 readings,	
the	concentration	of	cytochrome	b	 could	 then	be	determined	with	ε562-575	=	
28.5	mMcm-1	(Yu	et	al.	1974).	Alternatively	the	concentration	of	cyt.	bc1	was	




Multiple	 methods	 were	 used	 to	 attempt	 cytochrome	 bc1	
















A	 micro-seed	 stock	 was	 produced	 from	 successful	 crystal	 drops	 by	
crushing	 the	 crystal	with	 a	probe	and	 then	 subjecting	 them	 to	 vortexing	 in	
the	presence	of	 a	 seed	bead	 (Hampton	Research).	The	 seed	 stock	was	 then	
serially	 diluted	 in	 precipitant	 solution	 from	 the	 drop	 (D’Arcy	 et	 al.	 2007).	
Seed	stocks	were	either	used	fresh	or	after	being	stored	at	–	20	°C.		
	
Crystal	 drops	 incorporating	 seeds	 were	 set	 1:0.75:0.25	 (protein	 :	
precipitant	 :	 seeds)	using	30	mg/ml	cyt.	bc1	 in	KPi	buffer	with	DDM.	Drops	































Crystallisation	 was	 attempted	 following	 conditions	 by	 Huang	 et	 al.	
2005).	Protein	from	PEG	fraction	used	in	a	 final	buffer	of	Tris-HCl	(pH	7.5),	
0.5	mM	EDTA,	 0.1	%	UM.	Hexyl	β-D-glucopyranoside	 (Generon)	 (HG)	was	
added	as	solution	in	the	same	buffer	from	a	2.5	M	stock	to	a	concentration	of	
375	mM.	The	mixture	was	left	to	incubate	on	ice	for	at	least	30	minutes	prior	
to	 setting	 crystal	 trays.	 Protein	was	 set	 at	 concentrations	 of	 20	mg/ml,	 30	
mg/ml	 and	 40	 mg/ml	 against	 precipitant	 solutions	 of	 100	 mM	 sodium	
cacodylate	(pH	6.2	–	6.8),	20	mM	MgCl2,	3	mM	NaN3,	10	%	glycerol	and	5	–	10	
%	 PEG3350.	 Trials	 were	 set	 as	 hanging	 drops	 1:0.9:0.1	 protein	 to	 well	
solution	 to	 a	 minor	 precipitant.	 The	 minor	 precipitant	 was	 condition	 #31	
from	the	commercial	kit	Crystal	Screen	II	(Hampton	Research)	and	consisted	





drops	 using	 nylon	 loops	 on	 magnetic	 pins	 for	 cryo-crystallographic	 data	
collection	 (Hampton	Research).	 Crystal	 loop	 size	was	 best	matched	 against	
the	 size	 of	 the	 crystal	 to	 limit	 the	 amount	 of	 solvent	 left	 on	 the	 drop,	 and	
therefore	 limit	 background	 noise	 associated	 with	 solvent	 scatter.	 Crystal	
were	picked	from	the	drop	and	placed	in	prepared	cryoprotectants	that	had	
been	cooled	to	4	°C.	Crystals	were	allowed	to	soak	for	several	seconds	in	the	
cryoprotectant	 before	 being	 fished	 out	 and	 quickly	 plunged	 into	 liquid	






Crystals	 were	 transported	 on	 canes	 and	 kept	 submerged	 in	 liquid	
nitrogen	at	all	time	for	diffraction	screening	on	a	rotating	copper	anode	FRE+	
X-ray	source.	Data	were	recorded	on	a	MAR	CCD225.	Crystals	were	disposed	






Crystals	 were	 transferred	 to	 synchrotrons	 on	 loops	 in	 PUCKs	 and	
shipped	using	a	dry	shipping	dewar.	Data	were	collected	on	Proxima1,	Soleil,	
St-Aubin,	 France	 and	 I02,	 I04,	 I04-1	 and	 I24,	 Diamond	 Light	 Source	 (DLS),	
Oxfordshire,	 UK.	 Data	 were	 consistently	 measured	 using	 X-rays	 of	
wavelength	 0.9868	 Å.	 Attempts	 were	 made	 to	 fit	 beam	 size	 to	 the	 crystal	






Data	 were	 collected	 on	 I04	 at	 DLS	 and	 Proxima1	 at	 Soleil	 from	
multiple	 crystals	 until	 radiation	 damage	 diminished	 data	 quality	 and	
resolution.	Diffraction	 spots	 could	 be	 seen	 to	 3.2	Å.	 Frames	were	 recorded	
over	 0.5	 °	 oscillation	 and	 0.2	 s	 exposures	 with	 the	 X-ray	 beam	 at	 20	 %	






from	 single	 crystals	making	use	 of	 the	micro-focus	beam.	Overlapping	20	 °	
wedges	of	data	were	collected	at	points	on	the	crystal	before	translation	and	
further	 collection.	Up	 to	10	datasets	were	 collected	 from	each	 crystal.	Data	




The	methods	used	 in	data	 reduction	and	structural	 refinement	were	
common	 for	 all	 datasets.	 Data	 for	 cyt.	 bc1	 in	 complex	 with	 the	 pyridones	
GW844520	 and	 GSK932121	 was	 indexed,	 scaled	 and	 merged	 using	 Denzo	
and	 Scalepack	 in	 the	HKL2000	 suite	 (Otwinowski	&	Minor	 1997).	 Datasets	
for	 cyt.	bc1	 in	 complex	with	MJM	170	was	 indexed	using	 iMosflm	 (Leslie	&	
Powell	 2007;	 Battye	 et	 al.	 2011)	 and	merged	 using	 BLEND	 (Foadi	 &	 Aller	
2013)	 before	 being	 scaled	with	Aimless	 (Evans	&	Murshudov	 2013)	 in	 the	
CCP4	 suite	 (Collaborative	 Computational	 Project	 1994;	 Winn	 et	 al.	 2011).	
Initial	phases	where	produced	using	molecular	replacement	in	Molrep	(Vagin	
&	 Teplyakov	 1997)	 using	 PDB	 1PPJ	 with	 the	 ligands	 removed	 as	 a	model.	
Rigid	body	refinement	was	carried	out	 in	Refmac5	(Murshudov	et	al.	2011)	
prior	to	restrained	refinement.	Restrained	refinement	was	carried	out	using	
NCS	 restraints	 and	 additional	 secondary	 structure	 restraints	 generated	 by	
Prosmart	 (Nicholls	 et	 al.	 2012).	 Regions	 that	were	 observed	 to	 be	missing	
were	deleted	and	replaced	and	no	definitive	density	could	be	placed	for	the	
Rieske	 iron-sulphur	 protein	 for	 a	 single	 cyt.	 bc1	 monomer.	 Phospholipids	
were	built	into	the	electron	density	were	appropriate	and	extended	as	far	as	
the	density	allowed.	Ligands	were	built	using	 JLigand	(Lebedev	et	al.	2012)	
and	 placed	 in	 strong	 positive	 peaks	 of	 the	 Fo-Fc	 density	 map.	 Subsequent	
steps	 of	 manual	 model	 refinement	 in	 Coot	 (Emsley	 &	 Cowtan	 2004)	 and	
automated	 restrained	 refinement	 were	 carried	 out	 until	 reaching	 a	 final	





A	pET21d	plasmid	containing	 the	 rusticyanin	gene	 from	Thiobacillus	
ferrooxidans,	 the	 result	 of	many	years	 research,	was	kindly	 supplied	by	Dr.	
John	Hall.		
	








µg/ml	 ampicillin	 (Amp)	 as	 a	 selective	 marker.	 The	 plates	 were	 incubated	




=	 0.6.	 Protein	 expression	 was	 induced	 with	 1	 mM	 isopropyl	 β-D-1-
thiogalactopyranoside	(IPTG)	and	left	to	continue	growing	for	5	hours	at	37	
°C.	The	culture	was	then	spun	at	5000	g	for	10	mins	in	a	centrifuge	to	collect	










collected.	 Ammonium	 sulphate	 was	 added	 to	 the	 supernatant	 to	 60	 %	
saturation	and	 left	 to	 incubate	at	4	 °C	 for	1	hr	before	being	spun	at	21,000	
rpm	for	1	hr	at	4	°C	in	the	SS-34	rotor.	The	resulting	pellet	was	discarded	and	
further	 ammonium	 sulphate	was	 added	 to	 the	 supernatant	 until	 saturation	
before	being	 spun	under	 the	 same	conditions.	The	pellet	was	 collected	and	
resuspended	in	10	ml	100	mM	sodium	acetate	(pH	4)	before	being	dialysed	




left	 at	 4	 °C	 for	 1	 hour.	 Protein	 was	 removed	 from	 the	 dialysis	 tubing	 and	
loaded	on	a	3	ml	SP-sepharose	column	(GE	Healthcare),	pre-equilibrated	 in	
100	mM	 sodium	 acetate	 (pH	4),	 and	washed	with	 100	mM	 sodium	 acetate	
(pH	 4),	 200	mM	NaCl.	 Salt	 was	 increased	 in	 50	mM	 steps	 to	 500	mM	 and	
fractions	were	 collected.	 Rusticyanin	 containing	 fractions,	 notable	 for	 their	
blue	 colouration,	 were	 pooled	 and	 concentrated	 to	 1	 ml	 using	 an	 Amicon	
Ultra-15	 Centrifugal	 filter	 MWCO	 10	 kDa	 (Millipore)	 before	 being	 injected	
onto	 a	 HiLoad	 Superdex	 200	 pg	 16/60	 column	 (GE	 Healthcare)	 pre-
equilibrated	in	100	mM	sodium	acetate	buffer	(pH	4),	150	mM	NaCl	and	run	
at	 0.5	 ml/min.	 Rusticyanin	 was	 the	 only	 peak	 and	 protein	 containing	





Protein	was	 dialysed	 against	 10	mM	H2SO4	 overnight	 at	 4	 °C	 before	
being	 concentrated	 to	 10	 mg/ml	 for	 crystallisation.	 Crystal	 trays	 were	 set	
using	 2	 µl	 hanging	 drops	 (1:1)	 against	 a	 well	 solution	 of	 100	mM	 sodium	
citrate	 (pH	 4.5	 –	 5),	 200	 mM	 LiCl,	 23	 –	 26	 %	 PEG8000.	 Crystals	 took	
approximately	 1	 week	 to	 appear	 and	 took	 up	 to	 two	 weeks	 to	 reach	
maximum	 size.	 Crystals	 were	 then	 fished	 using	 nylon	 loops	 and	 dipped	 in	
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Data	was	 indexed	 in	P	21	using	 iMosflm	(Battye	et	al.	2011;	Leslie	&	
Powell	 2007)	with	 the	 unit	 cell	 32.02,	 59.60,	 36.79	 and	 90,	 106.1,	 90.	 The	
resulting	 data	 was	 then	 scaled	 with	 aimless	 to	 1.1	 Å	 resolution	 (Evans	 &	
Murshudov	2013).	Rigid	body	refinement	was	used	with	the	new	data	using	
the	model	PDB:2CAK.	Waters	and	 ligands	were	removed	to	create	an	 initial	
model	 for	 use	with	 the	 new	data.	 Restrained	 refinement	was	 subsequently	
carried	 out	 using	 Refmac5	 (Murshudov	 et	 al.	 2011).	 Alternating	 rounds	 of	
manual	 model	 building	 and	 multiple	 cycles	 of	 restrained	 refinement	 were	
carried	out	whilst	slowly	increasing	the	high	resolution	limit	of	the	data	used.	
Waters	 were	 added	 in	 Coot	 and	 then	 monitored	 in	 refinement	 using	






The	 sequence	 for	MSP119,	 corresponding	 to	 1526	 –	 1621	 of	Uniprot	
entry	 P04933,	 was	 codon	 optimised	 for	 Pichia	 pastoris	 expression	 and	
ordered	 from	 Genscript	 inserted	 in	 the	 SnaBI	 restriction	 site	 of	 pPIC9K	
	 118	
(Invitrogen).	 An	 N-terminal	 6x	 His	 tag	 was	 added	 with	 the	 DNA	 sequence	
CACCATCATCATCATCAC.	 The	 plasmid	 was	 amplified	 using	 E.	 coli	 Stellar	
Competent	 cells	 (Clontech).	 The	 cells	 were	 transformed	 with	 the	 plasmid	
using	the	same	protocol	as	used	in	section	6.2.1.	A	10	ml	LB	culture	with	100	





	 Pure	plasmid	DNA	was	 linearised	using	 the	 restriction	enzyme	SacI-
HF	(neb).	1.5	µg	of	DNA,	1	x	Cutsmart	buffer	and	1	µl	of	the	SacI-HF	enzyme	
were	incubated	in	50	µl	total	volume	and	left	for	1	hr	at	37	°C.	The	digested	




Electrocompetent	 P.	 pastoris	 SMD1168	 (Invitrogen)	 were	 thawed	
from	-80	°C	on	ice	and	transferred	to	an	electroporation	cuvette	with	2.0	mm	
gap	on	ice.	50	–	100	ng	of	linearised	DNA	was	added	to	the	cells	and	allowed	
to	 incubate	 for	 2	 mins.	 The	 electroporation	 cuvette	 was	 then	 placed	 in	 a	
GenePulser	II	(BioRad)	and	subjected	to	a	pulse	at	charging	voltage	1500	V,	
resistance	200	Ω	and	 capacitance	at	25	µF.	After	 the	pulse	 the	 cuvette	was	
placed	back	on	ice	and	1	ml	of	1	M	sorbitol	was	added.	The	cells	were	then	
taken	from	the	cuvette	and	plated	on	to	minimal	dextrose	media	plates	(MD)	
to	 select	 for	 yeast	 transformed	 with	 pPIC9K.	 Plates	 were	 placed	 in	 an	
incubator	at	29.4	°C	for	several	days	until	colonies	appeared.	
	
Cells	 were	 scraped	 from	 the	 MD	 plates	 and	 transferred	 in	 filtered	
water	on	to	yeast	extract,	peptone,	dextrose	media	(YPD)	supplemented	with	
the	G418	antibiotic.	Cells	were	 first	 transferred	 to	0.25	mg/ml	G418	plates	
and	left	to	grow	at	29.4	°C	until	colonies	appeared.	As	colonies	appeared	they	








spun	 down	 at	 1500	 g	 for	 10	 mins	 and	 transferred	 to	 a	 500	 ml	 culture	 of	
BMGY.	The	500	ml	culture	was	grown	as	before	until	 it	 reached	OD600	of	3.	
The	 cells	 were	 then	 spun	 down	 at	 1500g	 for	 10	 mins	 before	 being	
resuspended	 in	 buffered	 methanol-complex	 media	 (BMMY)	 for	 induction.	
Cells	were	grown	for	4	days	at	29.4	°C	and	260	rpm.	0.5	%	v/v	methanol	was	





filtered	 into	 sterile	 containers.	 The	 yeast	 pellet	 was	 discarded.	 The	
supernatant	 was	 pH’d	 to	 7.2	 using	 KOH	 and	 concentrated	 using	 a	 400	 ml	
stirred	 cell	 using	 ultrafiltration	 discs	 MWCO	 3	 kDa	 (Milllipore)	 under	
pressure	of	5	kPa.	5000	units	of	glycerol	free	PNGaseF	(neb)	were	added	to	
the	concentrated	solution	in	order	to	deglycosylate	the	protein.	The	reaction	
was	 left	 to	 run	 at	 37	 °C	 for	 four	 days.	 Successful	 deglycosylation	 was	
determined	by	differences	in	protein	migration	on	an15	%	SDS-PAGE.	
	
	 After	 deglycosylation,	 5	M	 NaCl	 was	 added	 to	 the	 protein	 to	 a	 final	





MWCO	 3500	 Da	 (Millipore).	 	 The	 concentrated	 protein	 was	 then	 further	
purified	and	buffer	 exchanged	using	a	16/60	Superdex	S75	 column	PG	 (GE	
	 120	










Rusticyanin	was	added	 to	MSP119	 to	excess	and	 left	 to	bind	at	 room	
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Vector	 maps	 of	 plasmids	 used	 in	 this	 study	 for	 protein	 expression	 with	
relevant	features	annotated	using	Snapgene.	
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